|
|
||||||||
Physiological Reviews, Vol. 81, No. 4, October 2001, pp. 1659-1688
Copyright ©2001 by the American Physiological Society
Howard Hughes Medical Institute, Laboratory of Molecular Biology and Biochemistry, The Rockefeller University, New York, New York
I. INTRODUCTION TO RHODOPSIN: A PROTOTYPICAL G PROTEIN-COUPLED RECEPTOR
II. MOLECULAR STRUCTURE OF RHODOPSIN
A. Overview of Rhodopsin Structure
B. Extracellular Surface Domain of Rhodopsin
C. Membrane-Embedded Domain of Rhodopsin
D. Chromophore-Binding Pocket
E. Cytoplasmic Surface Domain of Rhodopsin
III. MECHANISM OF THE OPSIN SHIFT AND SPECTRAL TUNING IN VISUAL PIGMENTS
IV. MOLECULAR MECHANISM OF RECEPTOR ACTIVATION
V. THE RHODOPSIN PHOTOCYCLE AND THE CHROMOPHORE REGENERATION PATHWAY
VI. INTERACTION OF R* WITH MOLECULES INVOLVED IN VISUAL TRANSDUCTION
VII. RHODOPSIN MUTATIONS AS A CAUSE OF HUMAN DISEASE
VIII. CONCLUSION
| |
ABSTRACT |
|---|
|
|
|---|
Menon, Santosh T.,
May Han, and
Thomas P. Sakmar.
Rhodopsin: Structural Basis of Molecular Physiology. Physiol. Rev. 81: 1659-1688, 2001.
The crystal structure of rod cell visual pigment
rhodopsin was recently solved at 2.8-Å resolution. A critical
evaluation of a decade of structure-function studies is now
possible. It is also possible to begin to explain the structural basis
for several unique physiological properties of the vertebrate visual system, including extremely low dark noise levels as well as high gain
and color detection. The ligand-binding pocket of rhodopsin is
remarkably compact, and several apparent chromophore-protein interactions were not predicted from extensive mutagenesis or spectroscopic studies. The transmembrane helices are interrupted or
kinked at multiple sites. An extensive network of interhelical interactions stabilizes the ground state of the receptor. The helix
movement model of receptor activation, which might apply to all G
protein-coupled receptors (GPCRs) of the rhodopsin family, is
supported by several structural elements that suggest how
light-induced conformational changes in the ligand-binding
pocket are transmitted to the cytoplasmic surface. The cytoplasmic
domain of the receptor is remarkable for a carboxy-terminal helical
domain extending from the seventh transmembrane segment parallel to the
bilayer surface. Thus the cytoplasmic surface appears to be
approximately the right size to bind to the transducin heterotrimer in
a one-to-one complex. Future high-resolution structural studies of
rhodopsin and other GPCRs will form a basis to elucidate the detailed
molecular mechanism of GPCR-mediated signal transduction.
| |
I. INTRODUCTION TO RHODOPSIN: A PROTOTYPICAL G PROTEIN-COUPLED RECEPTOR |
|---|
|
|
|---|
Rhodopsin (Rho) is a highly specialized G protein-coupled receptor (GPCR) that detects photons in the rod photoreceptor cell. Within the superfamily of GPCRs that couple to heterotrimeric G proteins, Rho defines the so-called class A GPCRs, which share primary structural homology (221, 232). Bovine Rho has been the most extensively studied GPCR. A large amount of pigment (0.5-1.0 mg) can be obtained from a single bovine retina by sucrose density gradient centrifugation preparation of the rod outer segment disk membranes (199). The pigment is stable enough in the dark that it can be further purified by various chromatographic procedures, and it remains stable in solubilized form in a variety of detergents (187). Bovine Rho was the first GPCR to be sequenced by amino acid sequencing (93, 193), the first to be cloned (174, 175), the first to be crystallized (186), and the first to yield a crystal structure (194).
Visual pigments share a number of structural features (222). Like all GPCRs, they consist of seven transmembrane segments (H1 to H7). A Lys residue that acts as the linkage site for the chromophore is conserved within H7 in all pigments, and a carboxylic acid residue that serves as the counterion to the protonated, positively charged Schiff base is conserved within H3. The position analogous to the Schiff base counterion is one helix turn away from the position of an Asp residue conserved in biogenic amine receptors that serves as the counterion to the cationic amine ligands. A pair of highly conserved Cys residues is found on the extracelluar surface of the receptor and forms a disulfide bond. A Glu(Asp)/Arg/Tyr(Trp) tripeptide sequence is found at the cytoplasmic border of H3. This sequence is conserved in class A GPCRs and has been shown to be involved in G protein interaction (68, 69). Sites of light-dependent phosphorylation at Ser and Thr residues are found at the carboxy-terminal tail of most visual pigments. These sites are analogous to phosphorylation sites found on the carboxy-terminal tails of other GPCRs (20).
Although it shares many similarities with other GPCR types, as a visual pigment Rho displays many specialized features not found in other GPCRs. In particular, visual pigments are made up of opsin apoprotein plus chromophore. The chromophore is not a ligand in the classical sense, since it is linked covalently via a protonated Schiff base bond to a specific Lys residue in the membrane-embedded domain of the protein (Fig. 1). The chromophore in all Rhos is derived from the aldehyde of vitamin A1, 11-cis-retinal (RET). Some fishes, amphibians, reptiles, and aquatic mammals may also employ the aldehyde of vitamin A2, 11-cis-3,4-didehydroretinal, which contains an additional carbon-carbon double bond. All pigments with a vitamin A2-derived chromophore are called porphyropsins. An important structural feature of the RET chromophore in Rho, in addition to its Schiff base linkage, is its extended polyene structure, which accounts for its visible absorption properties and allows for resonance structures (206).
|
Rho displays a broad visible absorption maximum (
max) at
~500 nm (Fig. 2). Photon capture
leading to photoisomerization of the 11-cis- to
all-trans-form of the RET chromophore is the primary event
in visual signal transduction, and it is the only light-dependent step (252). After photoisomerization, the pigment decays
thermally to metarhodopsin II (meta-II) with a
max value
of 380 nm. The meta-II intermediate is characterized by a
deprotonated Schiff base chromophore linkage. Meta-II is the active
form of the receptor (R*), which catalyzes guanine nucleotide exchange
by the rod cell heterotrimeric G protein transducin (Gt).
In contrast to vertebrate vision, invertebrate vision is generally
photochromic; a photoactivated invertebrate pigment can be inactivated
by absorption of a second photon that induces isomerization to the
ground-state cis-conformation.
|
In the case of the vertebrate visual system, Gt activation leads to the activation of a cGMP phosphodiesterase (cGMP PDE) and the closing of cGMP-gated cation channels in the plasma membrane of the rod cell. Light causes a graded hyperpolarization of the photoreceptor cell. The amplification, modulation, and regulation of the light response is of great physiological importance and has been discussed in detail elsewhere (17, 36, 236, 253). However, it should be pointed out that despite the fact that the visual system functions over about a 106-fold range of light intensity, the retinal rod cell has single photon detection capability due to extremely low levels of dark noise in Rho and a significant degree of biochemical amplification. Thermal isomerization in a single Rho molecule at physiological temperature has been estimated to occur about once in 470 years (16). The possibility of single pheromone molecule detection by insect olfactory systems notwithstanding, the visual system is unique among sensory signal transduction systems in that it can detect single events.
The gain and kinetics of activation in the vertebrate visual transduction cascade of the rod cell are of particular interest at the interface of biochemistry and physiology. Activation of a single Rho molecule by a single photon has been estimated to prevent the entry of as many as 107 cations into the rod cell. Recent studies have estimated that at room temperature each R* triggers activation of cGMP PDE at rates of 1,000-2,000 molecules/s (134). During the past 5 years, transgenic animal models have been employed to study the molecular basis of rod cell physiology in vivo (139). In addition, animal models have also begun to elucidate the molecular pathophysiology of human diseases that result from defects in visual transduction or in the biosynthesis of molecules in the signal transduction pathway.
This review attempts to outline the structural basis of the molecular physiology of vertebrate Rho. It will focus on what has been learned in this respect from the recently published crystal structure of Rho (194). What insight does the structure provide about the mechanism of the "opsin shift" and spectral tuning? What is the structural basis for the incredible stability of Rho in the rod cell disk membrane in the dark? How does Rho achieve high photochemical specificity and high quantum yield? How does a single R* catalyze guanine nucleotide exchange by hundreds of Gt molecules? What does the Rho structure tell us, if anything, about structure-activity relationships in other GPCRs? Finally, when possible, attempts are made to reconcile previous key findings from biochemical studies and the analysis of site-directed mutant pigments with the Rho crystal structure.
| |
II. MOLECULAR STRUCTURE OF RHODOPSIN |
|---|
|
|
|---|
A. Overview of Rhodopsin Structure
Rho is the first GPCR for which a crystal structure has been reported (194). To obtain crystals, bovine Rho was purified from rod outer segment membranes and crystallized from a detergent solution, nonyl-thiol-glucoside supplemented with the small amphiphile heptane 1,2,3-triol (186, 187). The resolution of the crystallographic data is ~2.8 Å, but small segments of the cytoplasmic surface domain are not resolved. The structure represents the inactive form of Rho with its bound RET chromophore intact. A ribbon diagram of the Rho peptide backbone structure with the RET chromophore is presented in Figure 3. The structure discussed in this review is that of the A chain in the crystal unit cell dimer.
|
As an integral membrane protein, Rho comprises three topological
domains: the extracellular surface, the membrane-embedded domain,
and the intracellular surface. Because of the location of Rho in the
disk membrane of the rod outer segment, the extracellular domain is
sometimes referred to as intradiscal. The amino terminus of Rho is
extracellular and the carboxy terminus is intracellular. The
membrane-embedded domain consists of seven transmembrane segments (H1 to H7), which are predominantly
-helical. The helical segments form a compact bundle that contains the binding site for the RET chromophore.
B. Extracellular Surface Domain of Rhodopsin
1. Crystal structure of the extracellular surface domain
The extracellular surface domain of Rho comprises the
amino-terminal tail (NT) and three interhelical loops (E1, E2, and
E3) (Fig. 1). There is significant secondary structure in the
extracellular domain and several intra- and interdomain interactions.
The extracellular domain essentially provides a stable foundation from
which the transmembrane segments extend (Fig. 3). NT extends from the amino terminus to Pro-34 and contains five
distorted strands ( In addition to the NT segment, the extracellular surface domain
comprises three extracellular interhelical loops: loop E1 (amino acids
101-106) connects H2 and H3, loop E2 (amino acids 174-199) connects
H4 and H5, and loop E3 (amino acids 278-285) connects H6 and H7. The
E1 loop runs along the periphery of Rho. Tyr-102 interacts with Pro-23
and Gln-28 to maintain proper orientation between E1 and NT. The E2
loop is extremely interesting in that it is folded deeply into the core
of the membrane-embedded region of Rho. In addition to contacts
with the RET chromophore, E2 forms extensive contacts with other
extracellular regions. Gly-174 and Met-183 cross the membrane surface.
The Met-183 side chain points toward a hydrophobic pocket around H1,
while the extended side chain of Gln-184 is surrounded by relatively
hydrophilic groups and a water molecule located close to the backbone
carbonyl group of Pro-180 and the hydroxyl group of Tyr-192. The
segment from Arg-177 to Glu-181 forms the The The carboxylic acid side chain of Glu-181 in the
1,
2, S3, S4, and S5). It is located in the
crystal structure just outside of loop E3, with the side chain of Asn-2
close to that of Asp-282 in E3. The NT domain also seems to be in
contact with the E3 loop in the area near Pro-12. The short
segment from Gly-3 to Pro-12 forms the first two antiparallel strands
in the structure (
1 and
2), which seem to lie roughly parallel to
the plane of the membrane. The segment Phe-13 to Pro-34 forms strands
S3 to S5, and they appear almost as a right triangle. S3 runs just
outside E3 and parallel to the long axis of the molecule. S4 connects
the dipeptide Ser-14/Asn-15 in NT with Pro-23, which is located close
to E1. S5 (Pro-27 to Pro-34) runs along the surface of the membrane
covering the extracellular space between H1 and H2. NT is glycosylated
at Asn-2 and Asn-15. The oligosaccharides extend away from the
extracellular domain and do not seem to interact with any part of the molecule.
3-strand, while that from
Ser-186 to Asp-190 forms the
4-strand.
3- and
4-strands run antiparallel. The
4-strand is
situated more deeply within the membrane-embedded region of Rho than the
3-strand. The
4-strand is adjacent to the RET
chromophore and forms the extracellular boundary, or roof, of the
ligand-binding pocket. A disulfide bond between Cys-187 and
Cys-110, which forms the extracellular end of H3, is highly conserved
among all class A GPCRs. The segment from Tyr-191 to Asn-200 forms a
short surface connector within E2 that is similar to both E1 and E3.
The backbone carbonyl group of Tyr-191 and the amide group of the side
chain of Gln-279, which is at the amino-terminal end of E3, lie in
close proximity. Within the connector portion of E2, Asn-199 is near to
Trp-175, although it is oriented differently in the unit cell chain B molecule.
3 sheet of the E2
loop points toward the center of the polyene chain of the retinylidene
chromophore (Fig. 4). Asp-190 at the
carboxy-terminal end of the
4-strand is interesting because
although it is near to the solvent-exposed surface of the receptor,
its carboxy group is partially buried. Solvent access to Asp-190 may be
controlled by Arg-177 and His-195, two amino acid residues with
functional side chains that could act to stabilize a partially buried
negative charge. Asp-190 is also strongly coupled to the chromophore by its flanking residues Ile-189 and Tyr-191 (Fig. 4).

View larger version (57K):
[in a new window]
Fig. 4.
The RET chromophore-binding pocket of bovine Rho. A:
a cut-away surface map is shown viewed from the extracellular
surface. All residues above the surface of RET were removed so that the
RET pocket can be appreciated. The protein is colored turquoise, and
the RET is colored in red. The side chains of Trp-265 (H6) and Lys-296
(H7) are labeled for orientation. The kink in RET at the
C10-C13 region of the polyene is clearly
defined. B: the RET chromophore-binding pocket is shown
from within the plane of the membrane bilayer. RET is colored magenta,
and amino acid side chains are colored yellow except for nitrogen atoms
(blue), oxygen atoms (red), and sulfur atoms (green). At least 16 amino
acid residues are within 4.5 Å of the RET ligand: Glu-113, Ala-117,
Thr-118, Gly-121, Glu-122, Glu-181, Ser-186, Tyr-191, Met-207, His-211,
Phe-212, Phe-261, Trp-265, Tyr-268, Ala-269, and Ala-292. Some
additional key amino acid residues are labeled, including the
Cys-110/Cys-187 disulfide bond. RET is situated such that its proximal
end (approximately C9 to C15) lies along the
4-strand and its distal end (approximately
C9 to the cyclohexenyl ring) lies along
H3.
One of the most striking and unexpected features of the
Rho structure is the presence and positioning of the
4-strand
(Ser-186/Cys-187/Gly-188/Ile-189), which forms the extracellular floor
of the RET binding site, secluding the ligand from bulk solution on the
extracellular surface. The
4-strand runs nearly parallel to the
length of the polyene chain from about C9 to the Schiff
base imine nitrogen. The opposite end of RET from the cyclohexenyl ring
to about C10 runs along H3, which is tilted with respect to
the plane of the membrane. The result is that this end of RET seems to
be held very firmly in place by multiple contacts (see sect.
IID).
The E3 loop essentially runs along the periphery of Rho in similar fashion to E1 and to the connector segment of E2 (amino acids 191-200). E3 displays at least two potential interactions with NT. Pro-12 of NT may interact with the E3 loop, and Asn-2 is close to Asp-282.
2. Structure-activity relationships in the extracellular surface domain
The role of the extracellular surface domain in Rho function has been elucidated by a number of studies involving site-directed mutagenesis. The extracellular loops and NT of bovine Rho have been shown in a deletion analysis to be important for proper folding of the receptor that allows cellular processing and chromophore binding (47). Insertional mutagenesis was also used in a related study to probe the topology of Rho and to correlate the location of epitope insertion to stability and cell trafficking (27). Interestingly, several mutations that interfered with the formation of a correct tertiary structure on the intradiscal surface resulted in mutant opsins that appeared to be retained in the endoplasmic reticulum during heterologous expression and were complexed with molecular chaperones (7). Antibody accessibility studies suggested that the NT domain constitutes a defined tertiary structure that contributes to the overall extracellular domain (35). This conclusion is supported by the crystal structure.
Rho is known to be glycosylated at Asn-2 and Asn-15 of the NT. A nonglycosylated Rho, which was prepared in the presence of tunicamycin, was defective in light-dependent activation of Gt (114). Site-directed opsin mutants with replacements of these two residues or of neighboring consensus sequence residues were studied as well. It was concluded that glycosylation at Asn-15 was required for full signal transduction activity, but apparently not for correct biosynthesis or folding (114). The structural basis of this findings is not clear from the Rho crystal structure since the oligosaccharide chains point away from the molecule and do not seem to engage in intramolecular interactions.
Future studies of mutant opsins with defects in folding, membrane insertion, or cell trafficking will be facilitated by the use of a methodology to purify regenerated pigment from nonregenerated opsin. The paradigm was developed by using the opsin mutant containing only three intradiscal Cys residues (112). It was shown that the nonregenerated opsin, which could not bind RET, was misfolded and was likely to have an incorrect disulfide bond pairing (213). This is additional evidence pointing to the role of the intradiscal domain, and in particular the early formation of a correct disulfide bond linkage between Cys-110 and Cys-187, in the proper folding of the opsin apoprotein (101).
The two conserved cysteine residues on the extracelluar domain, Cys-110 and Cys-187, are essential for proper folding of opsin expressed in COS cells (112). These two residues were shown to form a disulfide linkage in an elegant study in which the four intracellular and three membrane-embedded Cys residues were removed by site-directed mutagenesis to create a mutant receptor with only the three extracellular Cys residues remaining (111). In a related study, the double mutant C110A/C187A was shown to bind RET to form a Rho-like pigment (45). However, the meta-II-like photoproduct of the mutant pigment, which could activate Gt in response to light, was considerably less stable than native meta-II (45). In general, mutations on the extracellular surface that might interfere with the formation of a disulfide bond between residues Cys-110 and Cys-187 correlate with a loss of function phenotype. Namely, mutations affecting the ability of these two Cys residues to juxtapose during translation or membrane translocation affect expression level, transport to the plasma membrane, and the ability of the mutant opsin to bind RET chromophore to form a pigment with normal stability. The Cys-110/Cys-187 disulfide bond seems to stabilize the ground state structure of the chromophore-binding pocket, but the adjacent side chains must be able to acquire their proper positions even without the disulfide.
Several point mutations that result in amino acid substitutions in the NT domain are linked to autosomal dominant retinitis pigmentosa (ADRP), including positions Pro-23 and Gln-28. ADRP is an inherited human disease that causes progressive retinal degeneration, loss of dim-light vision, loss of peripheral vision, and eventual blindness. Pro-23 and Gln-28 interact with Tyr-102, which is in the E1 loop. This interaction might maintain an essential structural orientation between NT and E1 that is disrupted in the NT of the ADRP mutants. Thus Tyr-102 interacts with Pro-23 and Gln-28 to maintain proper orientation between E1 and NT. The roles of specific amino acid residues in the NT domain were also studied in various transgenic mice strains harboring point mutations that correspond to sites linked to ADRP. These transgenic strains are listed in Table 1.
|
The amino acids of the
4-strand are highly conserved among
vertebrate opsins. Of 130 opsins considered, 128 contained Ser and 2 contained Ala at position 186, 130 contained Cys at position 187, and
130 contained Gly at position 188. There was more variability at
position 189, where most opsins contained an Ile, but some contain Pro
or Val instead. In class A GPCRs that do not bind RET, for example,
adrenergic receptors, this region does not seem to be highly conserved,
except for the Cys-187 residue. Therefore, the
4-strand might serve
specifically to define the RET ligand-binding pocket in vertebrate opsins.
One particularly interesting interaction in this region is that of Ile-189 with RET C19 (the methyl group bonded to C9 of the polyene chain). Because the C19-methyl group is required for light-dependent activation of Rho, it would be interesting to determine the phenotype of the mutant I189A. The prediction would be that I189A would fail to activate Gt and would have a phenotype similar to that of 19-desmethyl Rho (opsin regenerated with the RET analog that lacks the C19-methyl group) (72). Otherwise, the RET C19-methyl group might interact with another part of Rho during activation, the RET C19-methyl group-Ile-189 contact being only a ground state interaction. A mutant such as I189W might have a decreased ability to bind RET, as would any mutant with a substitution at the neighboring Gly-188 residue. If they did bind RET, the phenotypes of these mutants with respect to Gt activation would also be interesting.
In Rho, Glu-181, which arises from the linker between
3 and
4 but
points toward the polyene chain, may serve a role in spectral tuning as
discussed below. In addition, Glu-181 may serve to influence the
electron density of the conjugated polyene system of the retinal chromophore so that photoisomerization occurs exclusively at the C11-C12 double bond. The corresponding His
residue in the green and red cone pigments constitutes a part of a
binding site for a chloride ion. Chloride binding causes a
spectroscopic red shift in the visible absorption spectra of green and
red pigments.
C. Membrane-Embedded Domain of Rhodopsin
1. Crystal structure of the membrane-embedded domain
The crystal structure of Rho suggests that 194 amino acid residues
make up the seven transmembrane segments (H1 to H7) included in the
membrane-embedded domain: H1 (amino acids 35-64), H2 (amino acids
71-100), H3 (amino acids 107-139), H4 (amino acids 151-173), H5
(amino acids 200-225), H6 (amino acids 247-277), and H7 (amino acids
286-306). The crystal structure of this domain is remarkable for a
number of kinks and distortions of the individual transmembrane segments, which are otherwise generally H1 has a very slight kink at Pro-53, its sole Pro residue. H2 begins
with Pro-71, and it is also kinked around vicinal Gly residues, Gly-89
and Gly-90 so that this region of H2 is brought closer to H3 than to
H1. This feature is interesting in that Gly-90 comes into close
proximity to the RET Schiff base counterion, Glu-113, on H3. H3 contains only a single Pro residue at its amino terminus, Pro-107.
Consecutive Gly residues in H3 at Gly-120 and Gly-121 do not seem to
distort H3 to the degree that Gly-89 and Gly-90 distort H2. The
cytoplasmic end of H3 contains the highly conserved Glu/Arg/Tyr motif
that is known to regulate Gt coupling. The
Glu-134/Arg-135/Tyr-136 tripeptide exhibits a slight deviation from a
regular helical structure. Several hydrophobic residues surround the
cytoplasmic end of H3 (Pro-71, Leu-72, Phe-148, Leu-226, Val-230,
Val-250 and Met-253), which might form a binding site for
Gt. Although H4 contains two consecutive Pro residues (Pro-170 and
Pro-171), significant distortion is only appreciated near the extracellular end of the segment. The cytoplasmic end of H4 is near to
H2, but the two segments seem to diverge beyond the level of Trp-161,
which is highly conserved in class A GPCRs. Irregular helicity is also
noted in the cytoplasmic end of H4. H5 appears to be nearly straight despite the presence of Pro-215, which
is approximately in the middle of the segment. However, helix
irregularity is noted, especially in the region near His-211. H5
contains six Phe residues and two Tyr residues. Tyr-223, which partially fills the interhelical region between H5 and H6, is highly conserved. The presence of Pro-267 creates a significant bend in H6 at about the
level of the Schiff base with respect to the putative membrane
boundaries. The boundary between C3 and H6 at the cytoplasmic surface
is highly basic due to presence of Lys-245, Lys-248, and Arg-252. H7 is the most highly distorted of the seven transmembrane helical
segments. There are kinks at two Pro residues, Pro-291 and Pro-303. In
addition, the helix is irregular around the region of residue Lys-296,
which is the chromophore attachment site. Pro-303 is a part of the
highly conserved Asn/Pro/X/X/Tyr motif (Asn-302/Pro-303/Val-304/Ile-305/Tyr-306 in Rho). 2. Structure-activity relationships in the
membrane-embedded domain
The membrane-embedded domain of Rho is characterized by the
presence of several intramolecular interactions that may be important in stabilizing the ground state structure of the receptor (Fig. 5). One of the hallmarks of the molecular
physiology of Rho is that it is essentially silent biochemically in the
dark. The RET chromophore serves as a potent pharmacological inverse
agonist to minimize activity. The result is that the rod cell can
attain single photon sensitivity (94). The Rho structure
reveals numerous potentially stabilizing intramolecular interactions,
some mediated by the RET chromophore and some arising mainly from
interhelical interactions that do not involve the RET-binding
pocket directly.
-helical in secondary structure. Many of these distortions from idealized secondary structure
were not accounted for in molecular graphics models of Rho based on
projection density maps obtained from cryoelectron microscopy
(12, 131, 227,
249).

View larger version (37K):
[in a new window]
Fig. 5.
Interhelical interactions in Rho. The structure of Rho is remarkable
for several interhelical interactions that are likely to stabilize the
ground state conformation of the receptor. In addition to several
hydrophobic interactions and interactions mediated by RET in the
membrane-embedded domain, three H-bond networks exist toward
the cytoplasmic side of the helical core of the receptor. H-bond
networks 1 and 3 involve highly conserved Asn/Pro/X/X/Tyr and
Glu/Arg/Tyr motifs, respectively. A detailed description of the
residues involved in the H-bond networks is presented in the text.
A: Rho is viewed from above the cytoplasmic surface of the
receptor and roughly perpendicular to the putative plane of the
membrane. The cytoplasmic loops and the carboxy-terminal tail
distal to H8 have been removed. Transmembrane helices H1 to H7 are
shown as discontinuous cylinders and are color coded as in Fig. 3.
B: Rho is viewed from within the membrane plane, and only
the cytoplasmic half of the transmembrane domain is presented. As in
A, the cytoplasmic loops and the carboxy-terminal tail
distal to H8 have been removed. Transmembrane helices H1 to H7 are
shown as discontinuous cylinders and are color coded as in Fig.
3.
The phenyl rings of the side chains of Phe-293 and Phe-294, both in H7, interact with Leu-40 in H1 and Cys-264 in H6, respectively. This interaction seems to be facilitated by the slight distortion of H6 in the region near Ile-263. In addition to these core interactions, there appear to be four H-bond networks that provide stabilizing interhelical interactions at or near the cytoplasmic surface of the receptor.
H-bond network 1 links H1, H2, and H7. The helical structure of H7 is elongated in the region from Ala-295 to Tyr-301, which permits the backbone carbonyl group of Ala-299 to H-bond with the side chains of Asn-55 in H1 and Asp-83 in H2. Asn-55 is a very highly conserved residue that plays the central role in the H-bond network 1 since it H-bonds to both Asp-83 and the backbone carbonyl of Ala-299. Asp-83, in turn, is connected to the backbone carbonyl of Gly-120 in H3 through a water molecule.
H-bond network 2 links H2, H3, and H4. This network involves Asn-78 as the key residue, which H-bonds to the hydroxyl functions of Ser-127 (H3), Thr-160 (H4), Trp-161 (H4), and the backbone carbonyl of Phe-159. Mutant pigments S127A and T160V displayed normal ground-state spectral properties consistent with a lack of direct contact with RET (103). Another possible interhelical interaction in this region might involve Glu-122 (H3), Met-163 (H4), and His-211 (H5). An indirect functional interaction between Glu-122 and His-211 has been demonstrated experimentally (18).
H-bond network 3 links H3 and H6. This network involves the conserved
Arg-135, which interacts with Glu-134 and with the hydroxyl group of
Thr-251 and side chain of Glu-247. The carboxylate of Glu-134 seems to
be in position to form a salt bridge with the guanidinium group of
Arg-135. This would be consistent with the hypothesis that Glu-134 is
unprotonated in Rho and becomes protonated during the transition to R*
(9, 59). It is interesting to note the three
consecutive Val residues (Val-137, Val-138, and Val-139) are situated
to form a cytoplasmic cap to H3 so that the Glu-134/Arg-135 dipeptide
is between the receptor core and the Val tripeptide. This Val cap might
act to stabilize the Glu-134/Arg-135 salt bridge, which in turn acts to
keep the receptor in its off state in the dark. It is also interesting
to note that Thr-251 in Rho is in the position equivalent to Ala-293 in
the
1B-adrenergic receptor. Mutation of Ala-293 causes
the receptor to become constitutively active (121). The
Asp(Glu)/Arg/Tyr(Trp) motif at the cytoplasmic border of H3 is one of
the most highly conserved structural motifs in class A GPCRs.
Finally, H-bond network 4 links H6 and H7. The key interaction here is between Met-257 and Asn-302. The precise functional importance of the highly conserved Asn/Pro/X/X/Tyr motif (Asn-302/Pro-303/Val-304/Ile-305/Tyr-306 in Rho) is unclear. However, one key structural role is to mediate several interhelical interactions. The side chains of Asn-302 and Tyr-306 project toward the center of the helical bundle. The hydroxyl group of Tyr-306 is close to Asn-73 (cytoplasmic border of H2), which is also highly conserved. A key structural water molecule may facilitate an H-bond interaction between Asn-302 and Asp-83 (H2). A recent mutagenesis study of the human platelet-activating factor receptor showed that replacement of amino acids at the positions equivalent to Asp-78 and Asn-302 in Rho with residues that could not H-bond prevented agonist-dependent receptor internalization and G protein activation (137).
The interaction between Met-257 and the Asn/Pro/X/X/Tyr motif was predicted earlier to explain the results of a mutagenesis study in which Met-257 was replaced by each of 19 other amino acid residues (91). Nearly all Met-257 replacements caused constitutive activity of the mutant opsins. A decrease in interaction between Met-257 and Asn-302 might relieve an interhelical constraint that stabilizes the ground state structure of Rho. However, the most highly constitutively active Met-257 mutants were M257Y, M257N, and M257S, which are all theoretically capable of forming H-bonds with the adjacent Asn-302. It is conceivable that the amino acid residue at position 257 in a mutant receptor forms H-bond interactions that stabilize the active state structure of the receptor as well. Whether constitutive activity is caused simply by a lack of H6/H7 interactions, or whether a gain of active state stabilizing interactions is required could be determined by testing mutant receptors with alterations of the Asn/Pro/X/X/Tyr motif, for example, N302A and I305A in Rho, or analogous mutations in other class A GPCRs.
It should be noted that the highly conserved Asn/Pro/X/X/Tyr (H7) and Glu/Arg/Tyr (H3) motifs play central roles in several of the core-stabilizing interactions described above. Their precise roles in the regulation of receptor activation will require knowledge about any structural reorientations that occur with respect to these residues in the formation of R*.
D. Chromophore-Binding Pocket
1. Crystal structure of the chromophore-binding pocket
The RET chromophore is a derivative of vitamin A1 with
a total of 20 carbon atoms (Fig. 1). The carbon atoms of the
cyclohexenyl ring are numbered C1 to C6. The
polyene carbons extend from C7 to C15. Two
methyl groups (C16 and C17) are bonded to
C1, and single methyl groups are attached at each of three
other carbons: C5 (C18 methyl), C9
(C19 methyl), and C13 (C20 methyl).
The structural conformation of the bound chromophore in the Rho crystal
structure appears to be 6-s-cis, 11-cis,
12-s-trans. The protonated Schiff base bond appears to be in
the anti conformation. A higher resolution Rho structure
would be required for a crystallographic determination of the precise
chromophore structure. Although a variety of spectroscopic studies
support the 6-s-cis, 11-cis,
12-s-trans RET conformation, recent NMR experiments
suggested a 6-s-trans conformation (80). The binding site of the RET chromophore lies within the
membrane-embedded domain of the receptor (Fig. 4). All seven
transmembrane segments and part of the extracellular domain contribute
interactions with the bound chromophore. The chromophore is located
closer to the extracellular side of the transmembrane domain of the
receptor than to the cytoplasmic side. The chromophore polyene from
C6 to C11 runs almost parallel to H3, which
provides many of the amino acid side chains that form the
chromophore-binding pocket: Glu-113, Gly-114, Ala-117, Thr-118,
Gly-120, and Gly-121. The polyene chain facing toward the extracellular
side of the receptor is covered, or capped, by the amino acid residues
from the Glu-113 serves as the RET Schiff base counterion. A number of
other amino acid side chains surround the imine moiety, including Tyr-43, Met-44, and Leu-47 in H1, Thr-94 in H2, and Phe-293 in H7. In
particular, Met-44 and Leu-47, in addition to the peptide bond between
Phe-293 and Phe-294, help to orient the side chain of Lys-296 in the
direction of the long axis of Rho. The phenyl rings of Phe-293 and
Phe-294 also interact with side chains of adjacent helices. The two
oxygen atoms of the Glu-113 carboxylate side chain of Glu-113 are
located 3.3 and 3.5 Å from the imine nitrogen. The hydroxyl group of
Thr-94 is also ~3.4 Å from one of the Glu-113 carboxylate oxygens.
Thr-92 and Thr-93 are also in the vicinity of the Schiff base imine but
may not be close enough to contribute significantly to stabilization of
its protonated ground state. The presence of water molecules in the
Schiff base region has been postulated, but the crystal structure at
the reported resolution does not contain defined water in this
region (168). The position of the cyclohexenyl ring of the chromophore is largely
constrained on the cytoplasmic side of the binding pocket by three
residues: Glu-122 (H3), Phe-261 (H6), and Trp-265 (H6). The indole side
chain of Trp-265 points inward from the more cytoplasmic position of
the Trp-265 backbone and comes within ~3.8 Å of the RET
C20. Side chains from Met-207, His-211, and Phe-212 on H5 and Tyr-268 and Ala-269 on H6 further constrain the chromophore ring. Gly-121 interacts with RET in a direct steric manner and lies closest
to the C18-methyl group bonded to C5 of the
cyclohexenyl ring (Gly-121 C H4 contributes only one residue, Cys-167, directly to the
chromophore-binding pocket. In summary, at least 16 amino acid residues are within 4.5 Å of
the RET moiety: Glu-113, Ala-117, Thr-118, Gly-121, Glu-122, Glu-181,
Ser-186, Tyr-191, Met-207, His-211, Phe-212, Phe-261, Trp-265, Tyr-268,
Ala-269, and Ala-292. The most striking feature of the RET binding
pocket is the presence of many polar or polarizable groups to
coordinate an essentially hydrophobic ligand (Fig. 4). 2. Structure-activity relationships in the
chromophore-binding pocket
A number of experimental approaches have been employed to
investigate RET-protein interactions in the membrane-embedded
domain of bovine Rho. Several spectroscopic methods such as resonance Raman spectroscopy (98, 128,
148), Fourier-transform infrared (FTIR)-difference
spectroscopy (60), and NMR spectroscopy (52, 80, 81, 251) have been reported.
Other approaches have included reconstitution of opsin apoprotein with
synthetic retinal analogs (97, 154) and
photochemical cross-linking (26, 170,
266). Early work on the structure and function of
recombinant bovine Rho focusing on the use of techniques of molecular
biology has been reviewed (116, 172). Lys-296 and Glu-113 are two of the key amino acid residues that define
the structure and function of the retinal chromophore in Rho. The
Schiff base linkage of the chromophore to Lys-296 is a key feature of
Rho structure (92). Light-dependent Schiff base
deprotonation is required for the formation of the active state of the
receptor R* (117, 153). However, it has been
shown that light can induce the receptor active state in the absence of
a Schiff base chromophore linkage to the opsin (268). In
this experiment, mutant opsin K296G was treated with a model retinal Schiff base compound prepared from 11-cis-retinal and
n-butyl amine. A visible pigment was formed, although no
linkage was present between the model compound and the opsin.
Photoisomerization of the model chromophore led to receptor activation
as judged by Gt activation. This demonstrates that opsin
can employ a diffusible ligand, which is analogous to
ligand-dependent GPCRs, such as biogenic amine receptors
(189). Glu-113 in bovine Rho serves as the counterion to the positive charge
of the RET protonated Schiff base (171, 225,
267). Glu-113 is unprotonated and negatively charged in
the ground state of Rho (57). It becomes protonated upon
light-dependent formation of meta-II and is the net proton
acceptor for the Schiff base proton (104). The
Glu-113-protonated Schiff base interaction serves to stabilize the
Schiff base proton such that its acid dissociation constant
(pKa) in Rho is estimated to be >12, compared with a value of ~7 for a model compound in aqueous solution, although the mechanism of protonated Schiff base stabilization is not entirely clear from the crystal structure. The stable interaction between Glu-113 and the protonated Schiff base may also inhibit hydrolysis of
the Schiff base linkage in darkness. For example, hydroxylamine does
not react with the Schiff base of Rho, but readily reacts with that of
meta-II or with Rho mutants in which Glu-113 is replaced by a
neutral amino acid residue by mutagenesis (225). This is an important consideration since the opsin alone, without the
RET chromophore, has a small but measurable activity (31,
207, 215, 244). The high
sensitivity of the rod cell depends on an extremely low intrinsic level
of signaling in darkness. Dark noise can be generated by thermal
isomerization events in Rho (14, 15,
262), by the presence of opsin lacking the RET chromophore, which acts as an inverse agonist, or by mutant opsins that
display the property of constitutive activity (215).
Constitutive activity refers to the ability of an opsin to activate
Gt in the absence of any chromophore. Generally, a mutation
that disrupts a putative salt bridge between Glu-113 and Lys-296 in the
opsin apoprotein leads to constitutive activity. Replacement of either Glu-113 or Lys-296 by a neutral amino acid results in a mutant opsin
with constitutive activity. Other mutations such as G90D or A292E also result in constitutive
activity, presumably because the introduction of the negatively charged
residue into the membrane-embedded domain of the receptor affects
the stability of the Glu-113/Lys-296 salt bridge (44, 207). The crystal structure shows that H2 is kinked around
vicinal Gly residues, Gly-89 and Gly-90, so that this region of H2 is brought closer to H3 than to H1. This feature is interesting in that
Gly-90 comes into close proximity to the retinylidene Schiff base
counterion, Glu-113, on H3. A mutation that results in the replacement
of Gly-90 by an Asp residue causes congenital stationary night
blindness in humans, probably because of destabilization of the ionic
interaction between Glu-113 and the Schiff base (269), or
because of constitutive activity of the mutant opsin apoprotein that
results from a disruption of a salt bridge between Glu-113 and Lys-296
(207). The mechanism of constitutive activity of opsins
and the potential relevance of constitutive activity to visual diseases
such as congenital night blindness has been reviewed (208). Opsin activity was reported to be only ~10 Glu-113 is not located near C12 of the retinal polyene as
predicted by two-photon spectroscopy and NMR spectroscopy of
retinal analogs and semiempirical quantum mechanical orbital
calculations (24, 82, 89,
90). However, the C12 of RET does interact with Glu-181 from the E2 loop. Glu-181 may serve to influence the
electron density of the conjugated polyene system of the RET chromophore so that photoisomerization occurs exclusively at the C11-C12 double bond. The potential ionic
interaction between RET and Glu-181 also suggests that it may have a
role in the mechanism of the opsin shift (see below). Perturbation of
the electron distribution near the center of the polyene chain is one
mechanism to facilitate spectral tuning (97). Glu-181 is highly conserved among vertebrate opsins, blue and
ultraviolet (UV) cone pigments. The corresponding position in green and
red cone pigments is His-197, which forms part of a chloride
ion-binding site. Chloride binding causes a red shift in absorption
of the green and red pigments. Interestingly, the H197E/R200Q mutant of
the human green cone pigment displays a visible The position of the cyclohexenyl ring of the chromophore is largely
constrained on the cytoplasmic side of the binding pocket by three
residues: Glu-122 (H3), Phe-261 (H6), and Trp-265 (H6). The indole side
chain of Trp-265 points inward from the more cytoplasmic position of
the Trp-265 backbone and comes within ~3.8 Å of the RET
C20. Trp-265 is close enough to RET that it can serve as an intrinsic probe of the chromophore conformation (149).
Side chains from Met-207, His-211, and Phe-212 on H5 and Tyr-268 and
Ala-269 on H6 further constrain the chromophore ring. Replacements of Phe-261 by Tyr or Ala-269 by Thr produce bathochromic spectral shifts
in the The interaction between Gly-121 and RET is consistent with mutagenesis
experiments in which replacement of Gly-121 caused blue-shifted
The Rho structure shows no interaction between Gly-121 and RET
C19 as was suggested by data from regeneration of mutants
with various chromophore analogs (83, 84).
However, the structure does not rule out the possibility that the two
are coupled together during activation, or that they may come into
proximity in R*, especially considering that Gly-121 replacement
mutants exhibit dark activity even with bound RET (83,
87). In these mutant opsins, RET displays partial agonist
activity. Regeneration of opsin with C20-desmethyl retinal
also produces a pigment with an increased level of basal activity in
the dark. E. Cytoplasmic Surface Domain of Rhodopsin
1. Crystal structure of the cytoplasmic surface domain
The cytoplasmic domain of Rho comprises three cytoplasmic loops
and the carboxy-terminal tail: C1 (amino acids 65-70), C2 (amino
acids 140-150), C3 (amino acids 226-246), and CT (amino acids
307-348). Loops C1 and C2 are resolved in the crystal structure, but
only residues 226 to 235 and 240 to 246 are resolved in C3. CT is
divided into two structural domains. C4 extends from the cytoplasmic
end of H7 at Ile-307 to Gly-324, just beyond two vicinal Cys residues
(Cys-322 and Cys-323), which are posttranslationally palmitoylated. The
remainder of CT extends from Lys-325 to the carboxy terminus of Rho at
Ala-348. The crystal structure does not resolve residues 328 to 333 in CT. Loop C1 displays a rigid structural organization that includes the
basic side chains of His-65, Lys-66, Lys-67, and Arg-69. The Lys-66 and
Arg-69 side chains point toward the bilayer. His-65 sits close to the
C4 loop at its H8 border. Lys-67 points toward the solvent and seems to
interact with CT, which runs nearly parallel to C1. Loop C2 resembles an L-shaped structure when it is viewed from a
vantage point parallel to the putative membrane plane. A short
H5 probably extends into the cytoplasmic region but breaks at the start
of C3 at Leu-226, which is immediately followed by an S-shaped loop
structure that lies nearly on the membrane surface. The loop extends
nearly to the lipid-facing side of H6 at Ala-235 and leaves a part
of the cytoplasmic surface of the seven helical bundle uncovered. The
region from Gln-236 to Glu-239 is absent in the crystal structure. The
polar side chains of Ser-240 and Thr-242 come close to a portion of CT
around Ser-334 to form a small cluster of hydroxyl groups. The
tetrapeptide Thr-243 to Ala-246 is The hallmark of the C4 loop is an The residues at the extreme carboxy-terminal end of CT compose the
most solvent exposed region of Rho. CT folds back over a small portion
of the helical bundle at H1 and H7. 2. Structure-activity relationships in the cytoplasmic domain
of rhodopsin
A number of cytoplasmic proteins are known to interact exclusively
with R*. Because the crystal structure depicts the inactive Rho
structure that does not interact significantly with cytoplasmic proteins, the structure can provide only indirect information about the
relevant R* state. In addition, two regions of the cytoplasmic surface
domain of Rho (amino acid residues 236-239 and 328-333) are not fully
resolved in the crystal structure. Potentially important structural
information relevant to understanding protein-protein interactions
in the visual transduction cascade may be lacking in the reported
structure. It should also be noted that the borders between the
transmembrane helical segments and the cytoplasmic loops do not
necessarily represent the boundary between aqueous phase and membrane
bilayer. The helical segments generally tend to extend into the
cytoplasmic aqueous phase. A number of amino acid residues that are
involved in Gt binding or activation, such as Glu-134 or
Lys-248, are situated in the helical segments. Perhaps the most extensively studied receptor-G protein interaction
is that of bovine Rho with Gt (96). Detailed
biochemical and biophysical analysis of the R*-Gt
interaction has been aided by mutagenesis of the cytoplasmic domain of
bovine Rho. Numerous Rho mutants defective in the ability to activate
Gt have been identified (69). Several of these
mutant receptors were studied by flash photolysis (55,
68), light scattering (54), or proton uptake
assays (9). The key overall result of these studies is
that C2, C3, and H8 are involved in R*-Gt interaction. This finding is consistent with other approaches including peptide competition studies (129, 155). Although several biochemical studies implicated CT in Gt
activation (201, 247), alanine-scanning
mutagenesis failed to confirm that the proximal portion of CT was
required (191, 259). Recently, a combination
of site-directed mutagenesis and peptide binding studies clearly
showed that the C4 loop region, which includes H8, is involved in
Gt binding and activation (55,
120, 155). Direct evidence for the
interaction between H8 and Gt comes from studies using a
synthetic peptide corresponding to Asn-310 to Leu-321 of Rho, which was
shown to bind to Gt (155). H8 is a cationic amphipathic helix that may bind a phospholipid
molecule, especially a negatively charged phospholipid such as
phosphatidylserine. In fact, spectroscopic evidence has been reported
to show an interaction between Rho and a lipid molecule that is altered
in the transition of Rho to meta-II (19,
103). High conservation of Phe-313 and Arg-314 suggests
that the amphipathic character of H8 may be functionally important. H8
points away from the center of Rho, and the area of the membrane
surface covered by the entire cytoplasmic surface domain appears to be
roughly large enough to accommodate Gt in a one-to-one complex. The CT distal to the palmitoylated Cys-322 and Cys-323 residues appears
to be highly disordered and dynamic based on the results of
site-directed electron paramagnetic resonance (EPR) spin labeling (135). However, the CT appears to encode essential
information concerning Rho sorting and targeting. Mutation of Pro-347
is associated with a biosynthetic cellular transport defect that leads
to ADRP (243). In addition, CT interacts with a
cytoplasmic dynein light-chain Tctex-1. The Rho-dynein
interaction controls the polarized targeting of Rho in the rod cell and
in polarized epithelial cells when ectopically expressed
(246). Conformational changes in the cytoplasmic surface domain that are
coupled to chromophore isomerization are discussed in detail in section
IV.
4-sheet (Ser-186 to Ile-189) of the E2 loop as described
above. The carboxylic acid side chain of Glu-181 in the
3-sheet of
the E2 loop points toward the center of the RET polyene chain.
-RET C18
distance 3.5 Å). Gly-121 is close to Phe-261 (H6) in the Rho crystal
structure. They pair to form one boundary of the RET binding site,
defining the C4-C5-C18 orientation (Phe-261 Cz-Gly-121 C
distance 5 Å; Phe-261
Cz-RET C4 distance 3.7 Å). This portion of the
RET binding pocket around H3 and H6 appears to be held rigidly together
by tight van der Waals interactions.
6 as much as
the activity of meta-II, a level much lower than previously
estimated (159). Therefore, the role of opsin activity in
bleaching desensitization and the pathophysiology of retinal
degeneration may be much less than previously suggested. Opsin can also
be activated without light by the addition of
all-trans-retinal or various retinal analogs
(31, 220). Expressed mutant opsins can also
be activated by various retinal analogs (88). These
results show that diffusible ligands can activate opsin and provide
information about the active-state conformation of Rho.
max
value of 500 nm (257), which is the same as the
max value of Rho, suggesting that perturbation of the
polyene by chloride may be the only element in the green cone pigment responsible for its spectral difference from Rho. The negative charge
of the chloride ion bound to His-197 in the long-wavelength sensing
cone pigments might be brought closer to RET than the charge of the
carboxylate of Glu-181 in Rho.
max values of the resulting mutant pigments
(38). These residues are also responsible in part for the
spectral shift in red cone pigments. Whereas red pigments have Thr and
Tyr at the positions corresponding to 261 and 269 in Rho, green cone pigments have Phe and Ala (11, 181).
max values and decreased RET binding that corresponded to the bulk of the substituted side chain (86).
Second-site replacement of Phe-261 by Ala caused a reversion of the
loss of function Gly-121 mutant phenotypes, which was interpreted to
mean that Gly-121 and Phe-261 interacted to form a part of the RET binding pocket (85). Gly-121 and Phe-261 are indeed very
close together in the Rho crystal structure. They pair to form one
boundary of the RET binding site to define the
C4-C5-C18 orientation (Phe-261 Cz-Gly-121 C
distance 5 Å; Phe-261
Cz-RET C4 distance 3.7 Å). Interestingly,
Gly-121 is conserved among all vertebrate and invertebrate visual
pigments (204), and Phe-261 is strictly conserved among
nearly all GPCRs (3). As described above, in
long-wavelength sensing cone pigments, Phe-261 is replaced by a
tyrosine that is involved in spectral tuning (38).
-barrel structure extends from Met-143 to Phe-146 along the main
long axis of Rho. A distinct cytoplasmic border seems to be formed by
the four polar side chains of Lys-141, Ser-144, Asn-145, and Arg-147.
C2 and C3 extend approximately to the same level above what appears to
be the cytoplasmic border of the receptor.
-helical.
-helical stretch, H8. H8 is
connected to H7 by the Met-309/Asn-310/Lys-311 tripeptide that acts as
a short linker. H8 lies nearly perpendicular to H7 and together with
the Asn/Pro/X/X/Tyr motif in H7 is one of the most highly conserved
long stretches of primary structure in Rho. The environment around H8
is mainly hydrophobic, which may lead to increased helical stability.
H8 might be best described as a cationic amphipathic
-helix, with
Lys-311 and Arg-314 on one face of the helix and Phe-313, Met-317, and
Leu-321 buried in the hydrophobic core of the bilayer between H1 and
H7. H8 points away from the center of Rho, and it appears that the
palmitoyl groups linked to Cys-322 and Cys-323 by thioester bonds may
be anchored in the membrane bilayer, although this is not resolved in
the crystal structure. The helical structure of H8 is terminated by
Gly-324.
| |
III. MECHANISM OF THE OPSIN SHIFT AND SPECTRAL TUNING IN VISUAL PIGMENTS |
|---|
|
|
|---|
The molecular interactions between the opsin protein and RET define the spectral properties of a particular visual pigment. The broad visible absorption peaks of visual pigments represent a collection of overlapping energy states. The absorbance at a particular wavelength can be viewed as the energy difference between the chromophore ground state energy and the energy of its first excited state. An increase in the energy gap causes a blue shift (hypsochromic shift) from a particular reference value. A decrease in the energy gap causes a red shift (bathochromic shift) from a particular reference value.
Rho has been used as a model pigment for a variety of chemical and
spectroscopic studies to elucidate the mechanism of the opsin shift. In
this context, the opsin shift may be defined as the difference between
the
max value of a RET Schiff base model compound
(~440 nm) in solution and that of Rho (500 nm). How is the positive
charge on the protonated Schiff base, which can be delocalized by the
conjugated polyene system, stabilized by the protein to create a unique
envelope of chromophore electronic distribution? One important result
to arise from the study of mutant bovine Rho pigments was the
identification of Glu-113 as the RET Schiff base counterion
(171, 225, 267). This result combined with the characterization of other membrane-embedded carboxylic acid residues by both UV-visible spectroscopy
(169, 171, 225,
267) and microprobe resonance Raman spectroscopy (151) suggested that the retinal-binding pocket in
bovine Rho was electrostatically neutral (24). Additional
studies including the use of photoaffinity reagents (170,
266), retinal analogs regenerated with site-directed
mutants (212), or site-directed mutant pigments
(85, 86, 149, 169)
led to a more complete picture of the amino acid residues in the
membrane-embedded domain of Rho that interact with the retinal chromophore.
The crystal structure now provides a clear picture of the RET
chromophore binding pocket in Rho (Fig. 4). One of the key surprises with respect to previous models of the opsin shift mechanism is Glu-181, which lies in the extracellular linker between
3 and
4 and points toward the
center of the polyene chain. Glu-181 is highly conserved among
vertebrate opsins, and blue and UV cone pigments. However, the
corresponding position in green and red cone pigments is His-197. An
extensive mutagenesis study of positively charged amino acids in human
middle (M-) and long (L-) wavelength sensitive pigments identified
His-197 and Lys-200 in E2 as the chloride ion binding site in these
pigments (257). Chloride binding in the M- and
L-sensing pigments causes a significant spectral red shift. It
seems plausible that a chloride ion held in place by His-197 and
Lys-200 might interact with the central portion of the polyene of RET
in these pigments.
Although the role of Glu-181 in the opsin shift in Rho has not yet been elucidated, data available to date suggest that the dominant mechanism responsible for the opsin shift is the interaction of dipolar amino acid residues with both the ground-state and excited-state charge distributions of the chromophore (127, 150). This general mechanism is supported by the crystal structure in that the RET binding pocket contains a large number of dipolar or polarizable amino acid residues.
Because the visual pigments of many species have been studied by
absorption spectroscopy or microspectrophotometry of visual organs, it
is straightforward to classify visual pigments solely on their visible
max values. Another common classification system is to
group visual pigments based on the photoreceptor cell type of the
retina in which they are found (29). Rod cells,
responsible for dim-light (scotopic) vision, contain Rho ("red"
opsin). Cone cells, responsible for bright-light (photopic) and
color vision, contain iodopsins ("violet" opsins), also known as
cone pigments or color vision pigments. The cloning and
characterization of opsins from a variety of species have allowed
further comparisons and phylogenetic classifications based on their
structural, spectral, and biochemical properties (8). The
homology in the opsin family of genes indicates that divergent
evolution occurred from a single precursor RET-binding protein to
form short (S-) and L-wavelength absorbing ancestors. The
L-sensing ancestor diverged to form L- and M-sensing pigments.
The S-wavelength sensing ancestor then diverged to form an
S-sensing pigment and the family of Rhos and Rho-like M-sensing
pigments. These evolutionary models can be tested experimentally by
ancestral gene reconstruction using gene synthesis methodology
(39, 40).
Whereas all Rho pigments generally absorb maximally at ~500 nm, the
max values of cone cell pigments vary. Individual cone pigments display
max values from the near UV (~380 nm)
to the far visible red (~600 nm). Different vertebrate species may
have more or fewer cone types, but all cone pigments share the same RET
(or 11-cis-3,4-didehydroretinylidene) chromophore.
Therefore, any differences in spectral properties among a collection of
cone pigments must be related to differences in the structures of their RET binding pockets, which is ultimately related to amino acid sequence, although not necessarily strictly related. Cone pigments also
display a number of other distinct biochemical properties, including
fast rates of R* decay and chromophore regeneration compared with those
of Rho. Specific amino acid residues in the chromophore-binding
pocket seem to control these biochemical properties independently of
spectral tuning (102).
Despite two centuries of study, the genetics, physiology, and psychophysics of human color vision remain of great interest. Human trichromatic color vision requires the presence of three physiological detection systems, which correspond to the three classes of photoreceptor cone cells. Each cone class (S-wavelength sensing, M-wavelength sensing, and L-wavelength sensing) contains a different pigment molecule. The peaks of absorbance are different for the three cone-cell pigments, but their absorbance spectra overlap considerably so that a combination of one, two, or three cone types reacts more or less strongly to a given light stimulus. A key element is that the response of a particular cone cell is the same no matter what the energy is of the photon that it captures (i.e., as long as chromophore isomerization occurs). Only the efficiency of photon capture varies with photon energy and the dynamic output relates only to the rate of photon capture. For example, in the simplest case of a human retina with only three individual cone cells, one cell of each class, chromatic lights would be perceived to be identical if they produced the same absorptions in all three cells, and different if they did not. Thus human trichromatic vision is the result of three independent comparisons of rates of photon absorption by the three cone types.
Three genomic and cDNA clones encoding the apoproteins of the human
cone pigments were cloned and characterized (177). The amino acid sequences of these opsins are ~41% identical to that of
human Rho. The M- and L-sensing opsins are ~96% identical to each other and ~43% identical to the S-sensing opsin.
Previously, the spectral properties of human cone pigments had been
studied by a variety of techniques ranging from psychophysical color
matching to microspectrophotometry (29). More recently,
the human cone pigment genes were expressed in tissue culture cell
lines, reconstituted with RET, and studied by UV-visible
spectroscopy (160, 190). The
max values reported in two studies were as follows: S
426 nm, M 530 nm, L 552 nm and 557 nm for polymorphic variants
(160); and S 424 nm, M 530 nm, and L 560 nm
(190). The
max value of the human
S-sensing pigment was recently reported to be 414 nm from a
measurement of its absolute spectrum (66). These studies also confirmed the correct functional assignments of the pigments that
had been based on genetic analysis of the cloned pigment genes.
Analysis of the arrangement of the cone opsin genes on the X chromosome has led to a preliminary understanding of the molecular genetics of inherited variations in color vision (176). In males with normal color vision it was proposed that a single L-sensing opsin gene resides with one or more M-sensing opsin genes in a head-to-tail tandem array. Thus, in one type of color vision defect, anomalous trichromacy, unequal intragenic recombination can theoretically result in an opsin gene that is a hybrid between M- and L-sensing genes. It was proposed that these hybrids would have anomalous spectral properties (176, 179). This hypothesis was confirmed experimentally at the level of the photoreceptor pigment by obtaining absorption spectra for heterologously expressed hybrid pigments responsible for anomalous trichromacy (161). Quantitative polymerase chain reaction (PCR) methods have been applied to evaluate in more detail the numbers and ratios of M- and L-wavelength sensing cone opsin genes in males with normal color vision. It was found that many subjects had more numerous cone opsin genes than previously suggested and that in many cases more than one L-wavelength opsin gene was present on the X chromosome (178, 180). The molecular genetics of blue cone monocromacy have also been investigated (173). A genetic model to account for the absence of the green and red genes has been tested in transgenic mice (256). The results suggest that a conserved 5'-region interacts with the green or red gene promoter to determine which gene is expressed in a given cone cell.
| |
IV. MOLECULAR MECHANISM OF RECEPTOR ACTIVATION |
|---|
|
|
|---|
Although the crystal structure of Rho does not provide direct information about the structure of R* or about the dynamics of the Rho to R* transition, it does provide a wealth of information that should help to design experiments using existing methods to address specific questions regarding the molecular mechanism of Rho activation. An inactive receptor conformation must be capable of changing to an active conformation, which catalyzes nucleotide exchange by a G protein. In Rho, the RET chromophore is in its "off" state, but switches to the "on" state 11-trans geometry by photoisomerization leading to the R* conformation of the receptor. Any amino acid side chain that is involved in such a conformational change must be able to exist in two different sterical and/or electrostatic states, which can be designated as on or off depending on whether the particular state is observed in the active or inactive receptor, respectively (62, 245).
Because receptor activation involves conformational changes at different topological locations, an individual amino acid or a structural domain in the chromophore-binding pocket may be in its on state without necessarily locking the Gt interaction domain into its active conformation, and vice versa. Thus a concerted transition of individual groups may create the overall active conformation, but it may not be clear whether or not all of the measurable structural changes are actually essential. A minimal subset of molecular groups may be able to govern the transition to an active receptor conformation irrespective of the binary states (off/on) of all possible groups usually participating in receptor activation. The functional hierarchy of individual group transitions may become obvious only in mutant, or in otherwise modified receptors, in which the state of an individual amino acid side chain can be influenced, or even locked, into one of two states. Ideally, it should be possible to alter the receptor activation pathway such that certain transitions become uncoupled from other transitions. It has been argued that the simplified binary model of individual molecular transitions provides a framework to analyze functional data obtained from recombinant Rhos (62, 91).
According to this argument, only molecular changes occurring between dark Rho and the R* state are relevant. Thus FTIR-difference spectroscopy has proven to be a well-suited technique for the study of light-induced conformational changes in retinal proteins (60, 218, 229). FTIR-difference spectroscopy measures frequency shifts of only those vibrational modes that are affected during photoproduct formation, irrespective of whether they are caused by the protein constituents or by the chromophore. In contrast, resonance Raman spectroscopy measures specifically chromophore vibrations and thereby helps to define the chromophore geometry and the Schiff base protonation state without the potential drawback of overlapping absorptions of amino acid side chains. Both techniques have contributed significantly to knowledge of molecular changes occurring during meta-II formation. Application of these techniques to site-directed Rho mutants has allowed the identification of a number of on/off states of particular amino acids during R* formation.
For example, among the membrane-embedded carboxylic acid groups, light-induced changes of protonation states or hydrogen-bond strengths were deduced from characteristic frequency shifts of C=O stretching vibrations of protonated carboxylic acid groups in FTIR-difference spectra. Their assignment to specific Asp or Glu residues was based on the disappearance of specific difference bands in site-directed mutants and revealed that Asp-83 (57, 209) and Glu-122 (57) are protonated in both dark Rho and meta-II, whereas Glu-113 is ionized in the dark state and becomes protonated in meta-II (104).
Evidence for the importance of steric interactions distal to the Schiff base comes from FTIR studies using ring-modified retinal analogs. Increased flexibility, as in 5,6-dihydro (71) or 7,8-dihydro analogs (196), reduces the usually observed torsions along the retinal chain in the intermediate trapped at 80 K where bathorhodopsin would normally be stable. In addition, the protein conformational changes observed at temperatures that stabilize the meta-I or meta-II intermediates differ from those observed in native Rho. In an extreme case, illumination of a pigment regenerated with a retinal analog lacking the cyclohexenyl ring fails to induce the complete set of infrared absorption changes typical of the meta-II conformation and results in reduced Gt activation (105). Therefore, the cyclohexenyl ring must transmit important steric changes to the protein. This model seems consistent with the location of the RET ring in the crystal structure of Rho.
Movement of
-helical domains is known to be involved in the signal
transduction mechanisms of some TM receptor proteins, such as the
bacterial chemoreceptors (162), and has been shown to
occur during the proton pumping cycle following retinal isomerization in bacteriorhodopsin (BR), the seven-transmembrane segment
light-driven proton pump (237-239). Recent studies
have suggested that steric and/or electrostatic changes in the
ligand-binding pocket of Rho may cause changes in the relative
disposition of TM helices within the core of the receptor. These
changes may be responsible for transmitting a "signal" from the
membrane-embedded binding site to the cytoplasmic surface of the
receptor. Trp mutagenesis (149), mutagenesis of conserved
amino acid residues on H3 and H6 (85, 86),
and the introduction of pairs of His residues at the cytoplasmic borders of TM helices to create sites for metal chelation
(228) have recently provided insights regarding the
functional role of specific helix-helix interactions in Rho.
The indole group of a Trp amino acid residue is often used as a
noninvasive environment-sensitive probe of protein structure because of its unique absorption and fluorescence properties. UV-absorption spectroscopy has suggested that the local protein environment around Trp residues changes during the conversion of Rho to
meta-II (205). In addition, a linear dichroism study of UV-difference bands indicated a reorientation of an indole side
chain during the meta-I to meta-II conversion
(37). To determine which Trp residues were responsible for
the absorbance changes previously reported, each of the five Trp
residues in Rho was replaced by either a phenylalanine or a tyrosine.
Replacements of Trp-126 and Trp-265 resulted in a decrease in the
magnitudes of the UV-difference peaks at 294 and 302 nm. These
results were consistent with a change of Trp-126 and Trp-265 to more
polar environments during activation of the receptor
(149). It was further suggested that the photoactivation
of Rho involved a change in the relative disposition of H3 and H6,
which contain Trp-126 and Trp-265, respectively, within the
-helical
bundle of the receptor.
H3 of Rho contributes many amino acid side chains that interact with RET, including Glu-113 and Gly-121. Replacement of Gly-121 resulted in a relative change of opsin selectivity for reconstitution with all-trans-retinal over RET in membranes. All-trans-retinal could efficiently bind and activate the mutant opsins, even though none of them displayed constitutive activity. The G121L replacement also caused RET to become a partial agonist in the G121L pigment (87). These results showed that H3, and Gly-121 in particular, were important in determining the specificity of the chromophore-binding pocket in Rho. The cyclohexenyl ring portion of the RET binding site is bordered by Gly-121 and Phe-261, consistent with the notion that functional interactions between H3 and H6 mediated by the chromophore are crucial for receptor photoactivation. Phe-261 was also found to be involved in the control of the decay of an early photointermediate (blue shifted intermediate) in a study of site-directed mutants by laser photolysis and rapid time-resolved absorption difference spectroscopy (106). Similar measurements of recombinant expressed Rho and Glu-113 counterion mutants were also recorded to provide a basis for understanding the relative movement of H3 and H6 required for receptor activation (107).
The functional interaction of H3 and H6 was further probed in a study in which metal ion binding sites were introduced between the cytoplasmic surfaces of transmembrane helices with the aim of restraining specific activation-induced conformational changes (228). Pairs of His residues are capable of chelating metal ions such as Zn(II) if the distance and geometry between the residues is appropriate. His residues substituted for the native amino acids at the cytoplasmic ends of H3 and H6, but not H5 and H7, created mutant proteins that were able to activate Gt in the absence, but not in the presence, of metal ions. It was concluded that specific metal-ion cross-links between positions 138 and 251, or 141 and 251, on H3 and H6, respectively, prevented receptor activation. These results indicated a direct coupling of receptor activation to a change in the spatial disposition of H3 and H6. This could occur if movements of H3 and H6 were coupled to changes in the conformation of the connected intracellular loops, which are known to contribute to binding surfaces and tertiary contacts of Rho with Gt (68, 69).
More direct evidence for changes in interhelical interactions upon receptor activation were provided by extensive site-directed spin labeling and EPR spectroscopy studies of the transition of Rho to R* in modified, or expressed mutant pigments. The results suggested a requirement for rigid body motion of transmembrane helices, especially H3 and H6, in the activation of Rho (65). A slight reorientation of helical segments upon receptor activation is also supported by experiments using polarized attenuated total reflectance infrared difference spectroscopy (46). Finally, movement of H6 was also detected by site-specific chemical labeling and fluorescence spectroscopy (51). The structural rearrangement of helices upon activation might not result in an R* structure that is drastically different from that of Rho since an engineered receptor with four disulfide bonds (between the cytoplasmic ends of H1 and H7 and H3 and H5, and the extracellular ends of H3 and H4 and H5 and H6) was still able to activate Gt (235).
Because the arrangement of the seven transmembrane segments is likely to be evolutionarily conserved among the family of GPCRs, the proposed motions of H3 and H6 may be a part of a conserved activation mechanism shared among all receptor subtypes (74, 110). In other class A GPCRs, agonist ligand binding would be coupled to a change in the orientations of H3 and H6. However, it should also be noted that the helix movement model of GPCR activation has been demonstrated so far only in the class A GPCR family. The recent crystal structure of the extracellular amino-terminal domain of a metabotropic glutamate receptor (mGluR) indicates that ligand-mediated receptor dimerization most likely plays a role in the activation mechanism (132). Other GPCRs in the class C family include the GABA receptor, the calcium-sensing receptor, and some pheromone receptors. Currently, the activation mechanism in the class B GPCRs, including the glucagon receptor and related peptide receptors, is not clear (250). It remains likely in both class B and C receptors that agonist binding, which requires the NT, causes TM helix movement to transmit a signal across the membrane.
Some conformational changes must occur at the cytoplasmic surface of Rho to produce R* that can activate Gt. Does the Rho structure provide any potential insights that might help to predict the identity of these conformational changes? Does H8 unwind or come off the membrane surface activation? Do C2 and C3, which are known to be important for Gt activation, move? What are the active state conformations of the conserved Glu-134/Arg-135/Tyr-136 in H3 and the conserved Asn-302/Pro-303/Val-304/Ile-305/Tyr-306 in H7?
Synthetic Rho-derived peptides have been shown to compete with native Rho for Gt binding (129, 155). This has allowed the identification of the C2, C3, and the proximal portion of CT as Gt binding sites. Site-directed mutagenesis has further characterized groups of amino acids in these regions implicated in Gt binding and activation (55, 68, 69, 155). Mutagenesis experiments can be designed to elucidate the light-dependent alterations of physical or chemical states of specific amino acids required for Gt activation. For example, structural changes in the cytoplasmic surface domain of Rho were suggested by changes in the reactivities of Cys residues introduced at various positions by site-directed mutagenesis (123). Conformation-dependent interhelical interactions and tertiary contacts on the cytoplasmic surface were also probed biochemically using site-directed disulfide bond formation (234) and/or expression of split receptors (264, 265). With the use of the core of Rho as a scaffold, cytoplasmic loops of other GPCRs were substituted for those of Rho; the results of G protein activation experiments suggested that C2 and C3 might have distinct roles in Gt activation and G protein subtype specificity (261). These results also indirectly support the general activation mechanism of helix movement that transmits a signal from the membrane-embedded cored to the surface loops of the receptor.
Additional biophysical methods have been employed to probe conformational changes at the cytoplasmic surface domain concomitant with receptor activation. FTIR spectroscopic determination of protonation states or hydrogen bonding of specific amino acid side chains on the cytoplasmic surface of Rho is less advanced than for residues in the hydrophobic core of the receptor. This is in part due to the relatively small contribution of water-exposed amino acids to infrared absorption changes in typical FTIR samples (hydrated films) (70). Recently, attenuated total reflectance (ATR) FTIR difference spectroscopy of the R*-Gt (or peptides derived from Gt) complex revealed an infrared difference band that could be assigned to protonation of Glu-134 (56, 61, 183).
Other techniques have been successful in monitoring light-dependent structural alterations occurring during meta-II formation as well. As measured by hydrogen-deuterium exchange of buried peptide groups using time-resolved FTIR spectroscopy, the kinetics of exchange in R* is increased. This result implies that buried regions of the peptide backbone structure become more accessible to solvent in forming meta-II (210). Light-dependent intramolecular charge movements in Rho can be monitored kinetically in vivo by recording an electroretinogram (ERG). The early phase of the ERG represents electrostatic potential in the oriented photoreceptor molecule. In fact, Rho displays a light-induced early receptor potential (ERP) akin to "gating currents" in voltage-dependent ion channels. Remarkably, the ERP can be recorded directly in giant cells that heterologously express Rho (223, 240). This method in combination with site-directed mutants may be able to identify specific amino acid side chains that move or exchange protons during the Rho photocycle.
Extensive site-directed spin labeling and EPR spectroscopy have been employed over the past 5 years to map the cytoplasmic domain of Rho (6, 33). EPR can provide information about side chain mobility, secondary structure, and solvent accessibility in both Rho and meta-II. Ultimately, this information can be assembled to form a map of structural changes that accompany receptor activation. Time-resolved (63) and static EPR spectroscopy studies (211) on site-specific spin-labeled Rho showed that the cytoplasmic terminations of H3 and H7 undergo structural rearrangements in the vicinities of Cys-140 and Cys-316, respectively. These changes have been specifically assigned to the meta-II conformation. Cys-140 is close to the highly conserved Glu-134/Arg-135/Tyr-136 tripeptide at the cytoplasmic border of H3.
Site-directed spin labeling of the amino acid residues from Tyr-306 to Leu-321 was also carried out. The information obtained regarding conformational changes in H8 upon meta-II formation was limited by the relative lack of reactivity of the Cys residues engineered into positions 317, 318, 320, and 321. However, structural changes were detected at positions 306, 313, and 316, consistent with movements of the nearby H6 and with biochemical evidence for a light-dependent interaction between Cys-65 and Cys-316 in native Rho (4, 32). Consistent with the notion of light-dependent structural changes in the vicinity of the cytoplasmic end of H7 is the observation that a monoclonal antibody with an epitope that was mapped to the amino acid sequence 304-311 bound only to R* and not to Rho (1). Only relatively small light-dependent structural changes were noted in and around the C1 loop when residues 56-75 were individually probed by site-directed spin labeling (5).
An EPR study of Rho mutants with a substitution of Glu-134 showed that the mutant receptors displayed an EPR signature consistent with a partially activated conformational state in the dark (118). This finding seems to be consistent with extensive earlier studies of Glu-134 replacement mutants. The structural change detected by EPR spectroscopy may be directly related to the apparent requirement for protonation of Glu-134 upon R* formation. A rearrangement of neighboring hydrogen-bonding partners may be necessary for protonation of Glu-134 to occur. The pH profile of Gt activation (59) as well as the abolishment of the uptake of two protons in mutant E134Q (9) suggests the existence of other titratable groups influenced by Glu-134. Glu-134 interacts primarily with Arg-135 in Rho, but it is not clear whether Glu-134 would interact with other side chains in R*, or simply be in a position to interact with bound Gt. The Glu-134/Arg-135 dipeptide may form a functional microdomain that is responsible for inducing the release of GDP from R*-bound Gt (2, 147).
Any model of receptor activation has to account for the fact that the chemical environment of the Schiff base is altered so that net proton transfer occurs between the Schiff base imine and Glu-113 (104). This change in the RET binding pocket must be transmitted to the cytoplasmic surface of the receptor. The Rho crystal structure is consistent with the helix movement model of receptor activation (65, 228) since it provides a structural basis to explain how chromophore isomerization could lead to displacement of H3 and H6 that would subsequently result in a change in orientation of Glu-134 at the cytoplasmic border. The structure suggests possible contacts between the cyclohexenyl ring of the chromophore and H3, which should change upon photoisomerization (26). At the Schiff base end of the chromophore, the C20 methyl group seems to interact with Trp-265, and this interaction should also change upon isomerization. Other key interhelical constraints are expected to be directly sensitive to chromophore isomerization, including those mediated by Phe-294, Ala-299, Asn-302, and Tyr-306. Any concerted disruption of stabilizing interhelical interactions may be expected to lead to helix movement and rearrangement of the helical bundle.
| |
V. THE RHODOPSIN PHOTOCYCLE AND THE CHROMOPHORE REGENERATION PATHWAY |
|---|
|
|
|---|
As outlined above, photoisomerization of the RET chromophore
induces the active receptor conformation R* from the inactive conformation Rho (30, 192, 263).
R* is spectroscopically indistinct from the Rho photoproduct
meta-II, which is characterized by an unprotonated Schiff base
chromophore linkage and a
max value of 380 nm. At low
temperature, a number of photointermediates that characterize the
transition of Rho to R* can be trapped and studied by a variety of
spectroscopic techniques. The classical photolysis pathway of Rho at
low temperatures proceeds according to the following scheme: Rho (500 nm)
bathorhodopsin (batho) (540 nm)
lumirhodopsin (lumi) (497 nm)
meta-I (478 nm)
meta-II (380 nm).
Laser flash photolysis coupled with nanosecond time-resolved
UV-visible spectroscopy has identified a related photocycle that occurs
at or near physiological temperature (124): Rho (500 nm)
batho (543 nm)
blue-shifted intermediate (BSI) (477 nm)
lumi (497 nm)
meta-I (480 nm)
meta-II (380 nm).
Meta-II decays to metarhodopsin III (meta-III) (450 nm) and finally
to opsin plus free 11-trans-retinal (141). The
chromophore photoisomerization occurs on an ultrafast time scale
and was observed to be a vibrationally coherent process
(255). The Rho photocycle is summarized in Figure 6.
|
Significant progress has been made in understanding structure-function relationships in the photointermediates of Rho through optical, resonance Raman, FTIR, NMR, and other spectroscopic studies on a variety of native visual pigments, chemically modified pigments, and artificial pigments (native opsins reconstituted with synthetic retinal analogs; Refs. 25, 57, 62, 67, 89, 122, 124, 142, 149, 151, 196, 203, 224, 229). These types of studies provide specific detailed information about chromophore structures and about dynamic chromophore-opsin interactions.
In addition to probing the chromophore, specific absorbance changes by aromatic residues can also be measured in early Rho photointermediates (140). Trp-265 is a useful probe of specific chromophore-protein interactions during the Rho photocycle, especially given its proximity to the RET chromophore. It can be probed by UV absorption spectroscopy, fluorescence spectroscopy, or UV resonance Raman spectroscopy (126). The photocycle can also be studied under a variety of conditions that might provide a basis for identifying specific amino acid residues that might be involved in intramolecular proton transfer reactions. For example, the pH dependency was determined for the formation of Rho photoproducts from lumi to meta-II (109). These types of experiments could be carried out with site-directed mutants as well in future studies.
R* becomes phosphorylated by Rho kinase, and its ability to activate Gt is diminished by the binding of arrestin to phosphorylated R*. The RET Schiff base linkage also becomes accessible to water in its R* conformation. Through an autocatalytic mechanism that involves Glu-113 (225), the RET Schiff base is hydrolyzed and all-trans-retinal (ATR) is released in the outer segment of the rod cell. ATR is reduced to all-trans-retinol in the outer segment by ATR dehydrogenase and NADPH. The all-trans-retinol is transported out of the rod cell where it binds to the interphotoreceptor retinoid-binding protein (IRBP). IRBP carries the all-trans-retinol to the retinal pigmented epithelium (RPE) where the chromophore is released and transported into the RPE cell. The all-trans-retinol (pro-R at C15) is palmitoylated by lecithin retinol acyl transferase (LRAT). Isomerohydrolase acts on the all-trans-retinyl ester to form 11-cis-retinol (pro-S at C15). The 11-cis-retinol is oxidized to RET by 11-cis-retinol dehydrogenase in the RPE cell endoplasmic reticulum lumen. The RET is released at the apical pole of the RPE cell where it binds to IRBP and is transported to the rod cell. The RET binds to the opsin apoprotein to regenerate a Rho pigment. The details of the chromophore regeneration pathway are presented elsewhere (206, 219).
How does the retinal chromophore enter or exit the membrane-embedded core of the opsin apoprotein? The extracellular surface domain is very well organized, with many half-buried hydrophobic cores as well as H-bond networks. Considering this fact and the hydrophobicity of RET, it seems reasonable to assume that the chromophore enters and exits the membrane-embedded core of the receptor via the membrane phospholipid bilayer. This implies that the chromophore would have to pass between two adjacent transmembrane helices. There is a much wider gap between H5 and H6 than between any of the other helix pairs, largely due to the numerous Phe residues along one face of H5. One or two of the Phe residues might be imagined to move back and forth to allow the ligand to enter or exit.
| |
VI. INTERACTION OF R* WITH MOLECULES INVOLVED IN VISUAL TRANSDUCTION |
|---|
|
|
|---|
Although studies of the photocycle intermediates of Rho provide
insights into dynamic changes in protein conformation and RET-protein interactions, R* is defined as the conformation that catalyzes guanine nucleotide exchange by Gt and propagates
and amplifies the signal of photon capture. R* is the key to the
biochemical amplification cascade of the vertebrate visual system (Fig.
7). R* is spectrally indistinct from the
meta-II photoproduct of Rho. Meta-II displays a
max value of 380 nm due in part to the presence of an
unprotonated RET Schiff base chromophore linkage. It is now widely
accepted that meta-II exists in two isospectral forms (meta-IIa and meta-IIb) that differ at least in
their protonation states (9, 10). Whereas
meta-IIa cannot bind to Gt,
meta-IIb may be identical to R*.
|
The transfer and amplification of signal from R* to Gt
involves specific interactions between the cytoplasmic surface domain of R* and at least two regions of Gt, the
carboxy-terminal tail of the
-subunit and the
carboxy-terminal tail of the
-subunit (73,
95, 119). In fact, the binding of
Gt, or certain peptides derived from Gt, can
stabilize R* (53, 120). The stabilization of
R* by Gt is related to the so-called "GTP effect"
originally described for hormone receptors in hepatocyte membrane
preparations (216). The molecular basis of the GTP effect
is that receptors are stabilized in their high-affinity agonist
conformation by the binding of G proteins. The addition of excess GTP
causes G protein dissociation, and receptors return to a
low-affinity agonist binding conformation. R* is stabilized in its
high affinity 11-trans chromophore-bound state by
interaction with Gt.
Perhaps the most extensively studied receptor-G protein interaction is that of bovine Rho with bovine Gt (96), which can both be purified readily from bovine retinas. Detailed biochemical and biophysical analysis of the R*-Gt interaction has been aided by mutagenesis of the cytoplasmic domain of bovine Rho. Numerous Rho mutants defective in the ability to activate Gt have been identified (69). Several of these mutant receptors were studied by flash photolysis (68), light scattering (54), proton uptake assays (9), or photoregeneration assays (55, 120). The salient results of these studies were that C2, C3, and CT (especially in the region involving H8) were involved in R*-Gt interaction. These findings were consistent with other approaches including peptide competition studies using native Rho (129). A class of interesting receptor mutants was also identified in which spectrally normal meta-II-like pigments were formed upon illumination. The photolyzed mutants bound Gt in the presence of GDP, but failed to release the bound Gt in the presence of GTP (54, 68). These results were consistent with the idea that Gt binding and Gt activation were discrete steps mechanistically, which could be uncoupled by specific amino acid substitutions on the cytoplasmic surface of the receptor.
A number of cytoplasmic proteins in addition to Gt are known to interact with R*. These include Rho kinase, which phosphorylates R* at specific serine residues (Ser-334, Ser-338, and Ser-343) (157, 184, 198). Reconstitution experiments suggest that light-dependent phosphorylation of Rho is catalyzed primarily by Rho kinase, and not by protein kinase C (185). Phosphorylation decreases the effective lifetime of R*, but paradoxically shifts the meta-I-meta-II equilibrium toward meta-II (75). Signal quenching requires that arrestin binds to phosphorylated R* to prevent it from activating Gt. The role of the distal carboxy-terminal tail in the shut-off of the light signal in the rod cell was shown convincingly in a study using a transgenic mouse strain. The mice, whose rod cells expressed a Rho transgene with a truncated carboxy-terminal tail, were studied by electrophysiological techniques. Phosphorylation of the carboxy-terminal tail was required for termination of light-induced signaling (42). A summary of some engineered animal models used to study rod cell physiology is presented in Table 1.
A detailed discussion of the use of physiological methods to address questions related to the termination of the flash response and to adaptation mechanisms has been presented (14, 15). For example, it appears that light adaptation cannot depend on high levels of phosphorylation of nonbleached Rho in rod cells (23). Light adaptation is regulated by intracellular calcium concentration. Intracellular calcium concentration is high in the dark but low in light-adapted rod cells. Although it is likely that the change in intracellular calcium concentration is detected by several cytoplasmic calcium-binding proteins that display calcium-dependent conformational changes (e.g., recoverin or S-modulin, isolated from bovine and frog rods, respectively), the mechanistic role of calcium, at least in terms of its effect on Rho phosphorylation, is not yet understood (115).
The biochemical mechanisms of background and light adaptation are known to involve light-dependent changes in intracellular concentrations of calcium as well as cGMP. Calcium levels influence the rate of accumulation of R* (133). However, the precise effects of changes of calcium and cGMP concentrations on the rate of recovery during adaptation remain to be determined (78). The details of the regulation of the biochemical activities of Rho kinase, phosducin, recoverin, Gt, and cGMP phosphodiesterase and their exact roles in signal termination and signaling system recovery and adaptation also remain to be elucidated in detail.
| |
VII. RHODOPSIN MUTATIONS AS A CAUSE OF HUMAN DISEASE |
|---|
|
|
|---|
Defects in G protein-mediated signaling are involved in the pathogenesis of a number of human diseases, both acquired and congenital (64, 231). The specific defects are often not fully understood, but two common themes of molecular pathophysiology generally emerge. First, the signal transduction machinery may be present and in its proper cellular location, but not properly functioning. Second, some element of the machinery may have failed to be properly synthesized, processed, or transported. These two paradigms appear to apply to Rho in cases of congenital stationary night blindness and retinitis pigmentosa, respectively.
Retinitis pigmentosa is a group of hereditary progressive blinding diseases with variable clinical presentations (21). One form of the disease, ADRP, was linked to a mutation in the gene for Rho (50). This first mutation discovered to be linked to ADRP was at codon 23 and would result in the change of a Pro residue to a His residue in the NT of Rho. Over 70 sites of rhodopsin mutation have been reported subsequently in ADRP patients (22, 28, 34, 48-50, 76, 156, 163, 197, 202, 226, 241). Recently, enough detailed phenotypic information has also been collected to attempt to group genotypes according to disease classes (43, 163).
Several studies have been carried out in which site-directed mutant opsin genes corresponding to ADRP genotypes were prepared (113, 164, 243). When expressed in tissue culture, the mutant opsins display a heterogeneity of spectral properties, biochemical properties, and cellular transport behavior. Some mutants are defective in chromophore binding, others in cellular transport and insertion into the plasma membrane. However, some mutations have no apparent effect in vitro. One particularly interesting mutation linked to retinal degeneration is a replacement of the Schiff base Lys-296 by Glu (K296E). This mutation should prevent chromophore Schiff base formation. Interestingly, the corresponding mutation in bovine Rho was shown to cause constitutive activity of the mutant opsin in Gt activation assays in vitro (215).
Significant work in this area has continued using transgenic mouse technology to produce mouse models of retinal degeneration. A summary of recent transgenic animal models is presented in Table 1. There appears to be no early developmental defect involving the retina in RP mouse models, and the work has potential relevance in understanding the molecular and cellular pathophysiology of some forms of ADRP (48, 50, 113, 241, 243). Transgenic mice expressing the P23H mutation on the intradiscal domain of Rho have been characterized, and results indicate that retinal degeneration may be due to improper mutant opsin expression and cellular transport (188, 217). Other interesting transgenic mouse models, such as those corresponding to mutations of the conserved residues Val-343 or Pro-347, point to a defect in targeting of the defective gene product to the rod cell outer segment (242). Rho mutants with alterations or deletions of these residues near the carboxy-terminal tail bind RET to form a pigment. In response to light, they activate Gt and are phosphorylated normally.
Further work is needed to clarify how the various Rho mutations associated with ADRP lead to photoreceptor cell death and to degeneration of the many cell layers of the retina. However, in the vast majority of cases it appears that the inherited single allelic mutation in the Rho gene allows the synthesis of a Rho protein that is in some way abnormal in structure such that its normal cellular processing or transport is prevented. Over time this defect leads to the activation of cellular apoptotic pathways that eventually result in rod cell death. The progression from rod cell death to retinal degeneration may involve local inflammatory reactions. The effects of nutritional vitamin A supplementation, at least in animal models, suggest a potential therapeutic benefit by stabilizing mutant opsins through increased chromophore availability (144).
Constitutive activity of mutant opsin G90D has also been implicated as a cause of congenital night blindness (207), a defect in scotopic vision in which the dark noise level of the rod cell is increased (230). The mutant pigment associated with congenital night blindness has been characterized in some detail (207, 269). A discussion of activating mutations of Rho and other GPCRs has also been reported (208). Other inherited mutations in the vicinity of the Schiff base in Rho might affect chromophore stability or cause constitutive activity without necessarily leading to rod cell apoptosis. Polymorphisms might also be expected to result in some heterogeneity in scotopic visual sensitivity among the general population.
| |
VIII. CONCLUSION |
|---|
|
|
|---|
The recent report of the crystal structure of bovine Rho provides a unique opportunity to address questions related to the structural basis of Rho physiology in the vertebrate visual transduction cascade. Over the past decade a remarkable amount of information about structure-activity relationships in Rho, and other GPCRs, has been obtained using techniques of molecular biology. The crystal structure of Rho also provides a chance to evaluate the quality of this information. Site-directed mutant pigments have been employed to elucidate key structural elements, the opsin-shift mechanism, and the mechanism of receptor photoactivation. Much of the past work on Rho was aided by reasonable molecular models based on projection density maps of the membrane-embedded domain of Rho obtained from cryoelectron microscopy of Rho in reconstituted bilayers.
Perhaps the biggest surprise in the crystal structure was the role of the extracellular surface domain in defining the RET binding pocket. Whether or not this feature carries over to other GPCRs remains to be determined. One particular advantage of studying Rho has been the opportunity to employ various spectroscopic methods, especially in combination with site-directed mutagenesis. Optical spectroscopy and resonance Raman spectroscopy are possible because of the presence of the RET chromophore, which is probed as a sensor of chromophore-protein interactions. Difference spectroscopy techniques, such as FTIR and UV-visible difference spectroscopy, make use of the chromophore as an optical switch. Over-expression of recombinant Rho allows a variety of biophysical methods to be used to address particular questions related to protein and chromophore conformational changes. The recent use of engineered animal models to study not only rod cell development and cellular pathophysiology but structure-physiology relationships as well has been unusually productive.
The important work of the future will involve questions related to the precise molecular mechanism of signal transduction by Rho. This will require some understanding of the dynamic changes in protein conformation, not only in Rho, but in the other proteins of the vertebrate visual cascade.
| |
ACKNOWLEDGMENTS |
|---|
We gratefully acknowledge the members of the Laboratory of Molecular Biology and Biochemistry at The Rockefeller University, including students, postdoctoral fellows, and associates, who have worked on visual phototransduction over the past 10 years. In addition, productive collaborations with several laboratories have been greatly appreciated.
Support was provided by National Institutes of Health Training Grants GM-07739 and EY-07138, the Charles H. Revson Foundation, the Aaron Diamond Foundation, the Arts and Letters Foundation, and the Allene Reuss Memorial Trust. T. P. Sakmar is an Associate Investigator of the Howard Hughes Medical Institute and an Ellison Foundation Senior Scholar.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: T. P. Sakmar, Rockefeller University, 1230 York Ave., New York, NY 10021 (E-mail: sakmar{at}mail.rockefeller.edu).
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Abdulaev NG, and Ridge KD.
Light-induced exposure of the cytoplasmic end of transmembrane helix seven in rhodopsin.
Proc Natl Acad Sci USA
95: 12854-12859, 1998 |
| 2. |
Acharya S, and Karnik SS.
Modulation of GDP release from transducin by the conserved Glu134-Arg135 sequence in rhodopsin.
J Biol Chem
271: 25406-25411, 1996 |
| 3. |
Alkorta I, and Du P.
Sequence divergence analysis for the prediction of seven-helix membrane protein structures. II. A 3-D model of human rhodopsin.
Protein Eng
7: 1231-1238, 1994 |
| 4. | Altenbach C, Cai K, Khorana HG, and Hubbell WL. Structural features and light-dependent changes in the sequence 306-322 extending from helix VII to the palmitoylation sites in rhodopsin: a site-directed spin-labeling study. Biochemistry 38: 7931-7937, 1999[Medline]. |
| 5. | Altenbach C, Klein-Seetharaman J, Hwa J, Khorana HG, and Hubbell WL. Structural features and light-dependent changes in the sequence 59-75 connecting helices I and II in rhodopsin: a site-directed spin-labeling study. Biochemistry 38: 7945-7949, 1999[Medline]. |
| 6. | Altenbach C, Yang K, Farrens DL, Farahbakhsh ZT, Khorana HG, and Hubbell WL. Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: a site-directed spin-labeling study. Biochemistry 35: 12470-12478, 1996[Medline]. |
| 7. |
Anukanth A, and Khorana HG.
Structure and function in rhodopsin. Requirements of a specific structure for the intradiscal domain.
J Biol Chem
269: 19738-19744, 1994 |
| 8. | Applebury ML, and Hargrave PA. Molecular biology of the visual pigments. Vision Res 26: 1881-1895, 1986[Web of Science][Medline]. |
| 9. |
Arnis S,
Fahmy K,
Hofmann KP, and Sakmar TP.
A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin.
J Biol Chem
269: 23879-23881, 1994 |
| 10. |
Arnis S, and Hofmann KP.
Two different forms of metarhodopsin II: Schiff base deprotonation precedes proton uptake and signaling state.
Proc Natl Acad Sci USA
90: 7849-7853, 1993 |
| 11. | Asenjo AB, Rim J, and Oprian DD. Molecular determinants of human red/green color discrimination. Neuron 12: 1131-1138, 1994[Web of Science][Medline]. |
| 12. | Baldwin JM, Schertler GF, and Unger VM. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 272: 144-164, 1997[Web of Science][Medline]. |
| 13. | Banin E, Cideciyan AV, Aleman TS, Petters RM, Wong F, Milam AH, and Jacobson SG. Retinal rod photoreceptor-specific gene mutation perturbs cone pathway development. Neuron 23: 549-557, 1999[Web of Science][Medline]. |
| 14. |
Baylor DA,
Lamb TD, and Yau KW.
The membrane current of single rod outer segments.
J Physiol (Lond)
288: 589-611, 1979 |
| 15. |
Baylor DA,
Lamb TD, and Yau KW.
Responses of retinal rods to single photons.
J Physiol (Lond)
288: 613-634, 1979 |
| 16. |
Baylor DA.
Photoreceptor signals and vision. Proctor lecture.
Invest Ophthalmol Vis Sci
28: 34-49, 1987 |
| 17. |
Baylor DA.
How photons start vision.
Proc Natl Acad Sci USA
93: 560-565, 1996 |
| 18. | Beck M, Sakmar TP, and Siebert F. Spectroscopic evidence for interaction between transmembrane helices 3 and 5 in rhodopsin. Biochemistry 37: 7630-7639, 1998[Medline]. |
| 19. | Beck M, Siebert F, and Sakmar TP. Evidence for the specific interaction of a lipid molecule with rhodopsin which is altered in the transition to the active state metarhodopsin II. FEBS Lett 436: 304-308, 1998[Web of Science][Medline]. |
| 20. | Benovic JL, Mayor F Jr, Somers RL, Caron MG, and Lefkowitz RJ. Light-dependent phosphorylation of rhodopsin by beta-adrenergic receptor kinase. Nature 321: 869-872, 1986[Medline]. |
| 21. |
Berson EL.
Retinitis pigmentosa: unfolding its mystery.
Proc Natl Acad Sci USA
93: 4526-4528, 1996 |
| 22. | Bessant DA, Khaliq S, Hameed A, Anwar K, Payne AM, Mehdi SQ, and Bhattacharya SS. Severe autosomal dominant retinitis pigmentosa caused by a novel rhodopsin mutation (Ter349Glu). Mutations in brief no 208 Online. Hum Mutat 13: 83, 1999[Medline]. |
| 23. |
Binder BM,
O'Connor TM,
Bownds MD, and Arshavsky VY.
Phosphorylation of non-bleached rhodopsin in intact retinas and living frogs.
J Biol Chem
271: 19826-19830, 1996 |
| 24. | Birge RR. Nature of the primary photochemical events in rhodopsin and bacteriorhodopsin. Biochim Biophys Acta 1016: 293-327, 1990[Medline]. |
| 25. |
Birge RR,
Murray LP,
Pierce BM,
Akita H,
Balogh-Nair V,
Findsen LA, and Nakanishi K.
Two-photon spectroscopy of locked-11-cis-rhodopsin: evidence for a protonated Schiff base in a neutral protein binding site.
Proc Natl Acad Sci USA
82: 4117-4121, 1985 |
| 26. |
Borhan B,
Souto ML,
Imai H,
Shichida Y, and Nakanishi K.
Movement of retinal along the visual transduction path.
Science
288: 2209-2212, 2000 |
| 27. |
Borjigin J, and Nathans J.
Insertional mutagenesis as a probe of rhodopsin's topography, stability, and activity.
J Biol Chem
269: 14715-14722, 1994 |
| 28. | Borrego S, Sanchez B, Ruiz A, and Antinolo G. Missense mutation A346P in the rhodopsin gene in one family with autosomal dominant retinitis pigmentosa. Hum Mutat 7: 180-181, 1996[Medline]. |
| 29. |
Bowmaker JK, and Dartnall HJ.
Visual pigments of rods and cones in a human retina.
J Physiol (Lond)
298: 501-511, 1980 |
| 30. | Bownds D. Site of attachment of retinal in rhodopsin. Nature 216: 1178-1181, 1967[Medline]. |
| 31. |
Buczylko J,
Saari JC,
Crouch RK, and Palczewski K.
Mechanisms of opsin activation.
J Biol Chem
271: 20621-20630, 1996 |
| 32. | Cai K, Klein-Seetharaman J, Farrens D, Zhang C, Altenbach C, Hubbell WL, and Khorana HG. Single-cysteine substitution mutants at amino acid positions 306-321 in rhodopsin, the sequence between the cytoplasmic end of helix VII and the palmitoylation sites: sulfhydryl reactivity and transducin activation reveal a tertiary structure. Biochemistry 38: 7925-7930, 1999[Medline]. |
| 33. |
Cai K,
Langen R,
Hubbell WL, and Khorana HG.
Structure and function in rhodopsin: topology of the C-terminal polypeptide chain in relation to the cytoplasmic loops.
Proc Natl Acad Sci USA
94: 14267-14272, 1997 |
| 34. | Capeans C, Blanco MJ, Lareu MV, Salas A, Pineiro A, Sanchez-Salorio M, and Carracedo A. 160Thr mutation in the rhodopsin gene associated with retinitis pigmentosa. Hum Hered 48: 237-240, 1998[Web of Science][Medline]. |
| 35. |
Cha K,
Reeves PJ, and Khorana HG.
Structure and function in rhodopsin: destabilization of rhodopsin by the binding of an antibody at the N-terminal segment provides support for involvement of the latter in an intradiscal tertiary structure.
Proc Natl Acad Sci USA
97: 3016-3021, 2000 |
| 36. | Chabre M. Trigger and amplification mechanisms in visual phototransduction. Annu Rev Biophys Biophys Chem 14: 331-360, 1985[Web of Science][Medline]. |
| 37. | Chabre M, and Breton J. Orientation of aromatic residues in rhodopsin. Rotation of one tryptophan upon the meta I to meta II transition after illumination. Photochem Photobiol 30: 295-299, 1979[Web of Science][Medline]. |
| 38. |
Chan T,
Lee M, and Sakmar TP.
Introduction of hydroxyl-bearing amino acids causes bathochromic spectral shifts in rhodopsin. Amino acid substitutions responsible for red-green color pigment spectral tuning.
J Biol Chem
267: 9478-9480, 1992 |
| 39. | Chang BSW, and Donoghue MJ. Recreating ancesteral proteins. Trends Ecol Evol 15: 109-117, 2000[Medline]. |
| 40. | Chang BSW, Kazmi MA, and Sakmar TP. Synthetic gene technology: application to ancestral gene reconstruction and structure-function studies of receptors. Methods Enzymol 343: 274-294, 2001[Web of Science]. |
| 41. | Chang GQ, Gaitan A, Hao Y, and Wong F. Correlation of DNA fragmentation and chromatin condensation in apoptotic nuclei of the Ser 6 mouse retina. Microsc Res Tech 36: 123-129, 1997[Web of Science][Medline]. |
| 42. |
Chen J,
Makino CL,
Peachey NS,
Baylor DA, and Simon MI.
Mechanisms of rhodopsin inactivation in vivo as revealed by a COOH-terminal truncation mutant.
Science
267: 374-377, 1995 |
| 43. |
Cideciyan AV,
Hood DC,
Huang Y,
Banin E,
Li ZY,
Stone EM,
Milam AH, and Jacobson SG.
Disease sequence from mutant rhodopsin allele to rod and cone photoreceptor degeneration in man.
Proc Natl Acad Sci USA
95: 7103-7108, 1998 |
| 44. | Cohen GB, Oprian DD, and Robinson PR. Mechanism of activation and inactivation of opsin: role of Glu113 and Lys296. Biochemistry 31: 12592-12601, 1992[Medline]. |
| 45. |
Davidson FF,
Loewen PC, and Khorana HG.
Structure and function in rhodopsin: replacement by alanine of cysteine residues 110 and 187, components of a conserved disulfide bond in rhodopsin, affects the light-activated metarhodopsin II state.
Proc Natl Acad Sci USA
91: 4029-4033, 1994 |
| 46. | DeLange F, Bovee-Geurts PH, Pistorius AM, Rothschild KJ, and DeGrip WJ. Probing intramolecular orientations in rhodopsin and metarhodopsin II by polarized infrared difference spectroscopy. Biochemistry 38: 13200-13209, 1999[Medline]. |
| 47. |
Doi T,
Molday RS, and Khorana HG.
Role of the intradiscal domain in rhodopsin assembly and function.
Proc Natl Acad Sci USA
87: 4991-4995, 1990 |
| 48. |
Dryja TP,
Hahn LB,
Cowley GS,
McGee TL, and Berson EL.
Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa.
Proc Natl Acad Sci USA
88: 9370-9374, 1991 |
| 49. |
Dryja TP,
McEvoy JA,
McGee TL, and Berson EL.
Novel rhodopsin mutations Gly114Val and Gln184Pro in dominant retinitis pigmentosa.
Invest Ophthalmol Vis Sci
41: 3124-3127, 2000 |
| 50. | Dryja TP, McGee TL, Reichel E, Hahn LB, Cowley GS, Yandell DW, Sandberg MA, and Berson EL. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 343: 364-366, 1990[Medline]. |
| 51. |
Dunham TD, and Farrens DL.
Conformational changes in rhodopsin. Movement of helix f detected by site-specific chemical labeling and fluorescence spectroscopy.
J Biol Chem
274: 1683-1690, 1999 |
| 52. |
Eilers M,
Reeves PJ,
Ying W,
Khorana HG, and Smith SO.
Magic angle spinning NMR of the protonated retinylidene Schiff base nitrogen in rhodopsin: expression of 15N-lysine- and 13C-glycine-labeled opsin in a stable cell line.
Proc Natl Acad Sci USA
96: 487-492, 1999 |
| 53. | Emeis D, Kuhn H, Reichert J, and Hofmann KP. Complex formation between metarhodopsin II and GTP-binding protein in bovine photoreceptor membranes leads to a shift of the photoproduct equilibrium. FEBS Lett 143: 29-34, 1982[Web of Science][Medline]. |
| 54. |
Ernst OP,
Hofmann KP, and Sakmar TP.
Characterization of rhodopsin mutants that bind transducin but fail to induce GTP nucleotide uptake. Classification of mutant pigments by fluorescence, nucleotide release, and flash-induced light-scattering assays.
J Biol Chem
270: 10580-10586, 1995 |
| 55. |
Ernst OP,
Meyer CK,
Marin EP,
Henklein P,
Fu WY,
Sakmar TP, and Hofmann KP.
Mutation of the fourth cytoplasmic loop of rhodopsin affects binding of transducin and peptides derived from the carboxy-terminal sequences of transducin alpha and gamma subunits.
J Biol Chem
275: 1937-1943, 2000 |
| 56. | Fahmy K. Binding of transducin and transducin-derived peptides to rhodopsin studies by attenuated total reflection-Fourier transform infrared difference spectroscopy. Biophys J 75: 1306-1318, 1998[Web of Science][Medline]. |
| 57. |
Fahmy K,
Jager F,
Beck M,
Zvyaga TA,
Sakmar TP, and Siebert F.
Protonation states of membrane-embedded carboxylic acid groups in rhodopsin and metarhodopsin II: a Fourier-transform infrared spectroscopy study of site-directed mutants.
Proc Natl Acad Sci USA
90: 10206-10210, 1993 |
| 58. | Fahmy K, and Sakmar TP. Light-dependent transducin activation by an ultraviolet-absorbing rhodopsin mutant. Biochemistry 32: 9165-9171, 1993[Medline]. |
| 59. | Fahmy K, and Sakmar TP. Regulation of the rhodopsin-transducin interaction by a highly conserved carboxylic acid group. Biochemistry 32: 7229-7236, 1993[Medline]. |
| 60. | Fahmy K, Sakmar TP, and Siebert F. Structural determinants of active state conformation of rhodopsin: molecular biophysics approaches. Methods Enzymol 315: 178-196, 2000[Web of Science][Medline]. |
| 61. | Fahmy K, Sakmar TP, and Siebert F. Transducin-dependent protonation of glutamic acid 134 in rhodopsin. Biochemistry 39: 10607-10612, 2000[Medline]. |
| 62. | Fahmy K, Siebert F, and Sakmar TP. Photoactivated state of rhodopsin and how it can form. Biophys Chem 56: 171-181, 1995[Web of Science][Medline]. |
| 63. |
Farahbakhsh ZT,
Hideg K, and Hubbell WL.
Photoactivated conformational changes in rhodopsin: a time-resolved spin label study.
Science
262: 1416-1419, 1993 |
| 64. |
Farfel Z,
Bourne HR, and Iiri T.
The expanding spectrum of G protein diseases.
N Engl J Med
340: 1012-1020, 1999 |
| 65. |
Farrens DL,
Altenbach C,
Yang K,
Hubbell WL, and Khorana HG.
Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin.
Science
274: 768-770, 1996 |
| 66. | Fasick JI, Lee N, and Oprian DD. Spectral tuning in the human blue cone pigment. Biochemistry 38: 11593-11596, 1999[Medline]. |
| 67. | Feng X, Verdegem PJ, Eden M, Sandstrom D, Lee YK, Bovee-Geurts PH, de Grip WJ, Lugtenburg J, de Groot HJ, and Levitt MH. Determination of a molecular torsional angle in the metarhodopsin-I photointermediate of rhodopsin by double-quantum solid-state NMR. J Biomol NMR 16: 1-8, 2000[Web of Science][Medline]. |
| 68. |
Franke RR,
Konig B,
Sakmar TP,
Khorana HG, and Hofmann KP.
Rhodopsin mutants that bind but fail to activate transducin.
Science
250: 123-125, 1990 |
| 69. |
Franke RR,
Sakmar TP,
Graham RM, and Khorana HG.
Structure and function in rhodopsin. Studies of the interaction between the rhodopsin cytoplasmic domain and transducin.
J Biol Chem
267: 14767-14774, 1992 |
| 70. | Ganter UM, Charitopoulos T, Virmaux N, and Siebert F. Conformational changes of cytosolic loops of bovine rhodopsin during the transition to metarhodopsin-II: an investigation by Fourier transform infrared difference spectroscopy. Photochem Photobiol 56: 57-62, 1992[Web of Science][Medline]. |
| 71. | Ganter UM, Kashima T, Sheves M, and Siebert F. FTIR evidence of an altered chromophore-protein-interaction in the artificial visual pigment cis-5,6-dihydroisorhodopsin and its photoproducts BSI, lumirhodopsin and metarhodopsin-I. J Am Chem Soc 113: 4087-4092, 1991. |
| 72. | Ganter UM, Schmid ED, Perez-Sala D, Rando RR, and Siebert F. Removal of the 9-methyl group of retinal inhibits signal transduction in the visual process. A Fourier transform infrared and biochemical investigation. Biochemistry 28: 5954-5962, 1989[Medline]. |
| 73. | Garcia PD, Onrust R, Bell SM, Sakmar TP, and Bourne HR. Transducin-alpha C-terminal mutations prevent activation by rhodopsin: a new assay using recombinant proteins expressed in cultured cells. EMBO J 14: 4460-4469, 1995[Web of Science][Medline]. |
| 74. |
Gether U, and Kobilka BK.
G protein-coupled receptors. II. Mechanism of agonist activation.
J Biol Chem
273: 17979-17982, 1998 |
| 75. | Gibson SK, Parkes JH, and Liebman PA. Phosphorylation alters the pH-dependent active state equilibrium of rhodopsin by modulating the membrane surface potential. Biochemistry 38: 11103-11114, 1999[Medline]. |
| 76. | Goliath R, Bardien S, September A, Martin R, Ramesar R, and Greenberg J. Rhodopsin mutation G109R in a family with autosomal dominant retinitis pigmentosa. Hum Mutat Suppl 1: S40-S41, 1998. |
| 77. |
Goto Y,
Peachey NS,
Ripps H, and Naash MI.
Functional abnormalities in transgenic mice expressing a mutant rhodopsin gene.
Invest Ophthalmol Vis Sci
36: 62-71, 1995 |
| 78. | Gray-Keller MP, and Detwiler PB. Ca2+ dependence of dark- and light-adapted flash responses in rod photoreceptors. Neuron 17: 323-331, 1996[Web of Science][Medline]. |
| 79. |
Green ES,
Menz MD,
LaVail MM, and Flannery JG.
Characterization of rhodopsin mis-sorting and constitutive activation in a transgenic rat model of retinitis pigmentosa.
Invest Ophthalmol Vis Sci
41: 1546-1553, 2000 |
| 80. | Grobner G, Burnett IJ, Glaubitz C, Choi G, Mason AJ, and Watts A. Observations of light-induced structural changes of retinal within rhodopsin. Nature 405: 810-813, 2000[Medline]. |
| 81. | Grobner G, Choi G, Burnett IJ, Glaubitz C, Verdegem PJ, Lugtenburg J, and Watts A. Photoreceptor rhodopsin: structural and conformational study of its chromophore 11-cis retinal in oriented membranes by deuterium solid state NMR. FEBS Lett 422: 201-204, 1998[Web of Science][Medline]. |
| 82. | Han M, DeDecker BS, and Smith SO. Localization of the retinal protonated Schiff base counterion in rhodopsin. Biophys J 65: 899-906, 1993[Web of Science][Medline]. |
| 83. |
Han M,
Groesbeek M,
Sakmar TP, and Smith SO.
The C9 methyl group of retinal interacts with glycine-121 in rhodopsin.
Proc Natl Acad Sci USA
94: 13442-13447, 1997 |
| 84. | Han M, Groesbeek M, Smith SO, and Sakmar TP. Role of the C9 methyl group in rhodopsin activation: characterization of mutant opsins with the artificial chromophore 11-cis-9-demethylretinal. Biochemistry 37: 538-545, 1998[Medline]. |
| 85. |
Han M,
Lin SW,
Minkova M,
Smith SO, and Sakmar TP.
Functional interaction of transmembrane helices 3 and 6 in rhodopsin. Replacement of phenylalanine 261 by alanine causes reversion of phenotype of a glycine 121 replacement mutant.
J Biol Chem
271: 32337-32342, 1996 |
| 86. |
Han M,
Lin SW,
Smith SO, and Sakmar TP.
The effects of amino acid replacements of glycine 121 on transmembrane helix 3 of rhodopsin.
J Biol Chem
271: 32330-32336, 1996 |
| 87. |
Han M,
Lou J,
Nakanishi K,
Sakmar TP, and Smith SO.
Partial agonist activity of 11-cis-retinal in rhodopsin mutants.
J Biol Chem
272: 23081-23085, 1997 |
| 88. | Han M, and Sakmar TP. Assays for activation of recombinant expressed opsins by all-trans-retinals. Methods Enzymol 315: 251-267, 2000[Web of Science][Medline]. |
| 89. | Han M, and Smith SO. High-resolution structural studies of the retinal-Glu113 interaction in rhodopsin. Biophys Chem 56: 23-29, 1995[Web of Science][Medline]. |
| 90. | Han M, and Smith SO. NMR constraints on the location of the retinal chromophore in rhodopsin and bathorhodopsin. Biochemistry 34: 1425-1432, 1995[Medline]. |
| 91. | Han M, Smith SO, and Sakmar TP. Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6. Biochemistry 37: 8253-8261, 1998[Medline]. |
| 92. | Hargrave PA, Bownds D, Wang JK, and McDowell JH. Retinyl peptide isolation and characterization. Methods Enzymol 81: 211-214, 1982[Web of Science][Medline]. |
| 93. | Hargrave PA, McDowell JH, Curtis DR, Wang JK, Juszczak E, Fong SL, Rao JK, and Argos P. The structure of bovine rhodopsin. Biophys Struct Mech 9: 235-244, 1983[Web of Science][Medline]. |
| 94. |
Hecht S,
Shaler S, and Pirene MH.
Energy, quanta, and vision.
J Gen Physiol
25: 819-840, 1942 |
| 95. | Helmreich EJ, and Hofmann KP. Structure and function of proteins in G-protein-coupled signal transfer. Biochim Biophys Acta 1286: 285-322, 1996[Medline]. |
| 96. | Hofmann KP, Jager S, and Ernst OP. Structure and function of activated rhodopsin. Israel J Chem 35: 339-355, 1995. |
| 97. | Honig B, Dinur U, Nakanishi K, Balogh-Nair V, Gawinowicz MA, Arnaboldi M, and Motto M. An external point-charge model for wavelength regulation in visual pigments. J Am Chem Soc 101: 7084-7086, 1979. |
| 98. | Huang L, Deng H, Koutalos Y, Ebrey T, Groesbeek M, Lugtenburg J, Tsuda M, and Callender RH. A resonance Raman study of the C=C stretch modes in bovine and octopus visual pigments with isotopically labeled retinal chromophores. Photochem Photobiol 66: 747-754, 1997[Web of Science][Medline]. |
| 99. |
Huang PC,
Gaitan AE,
Hao Y,
Petters RM, and Wong F.
Cellular interactions implicated in the mechanism of photoreceptor degeneration in transgenic mice expressing a mutant rhodopsin gene.
Proc Natl Acad Sci USA
90: 8484-8488, 1993 |
| 100. | Humphries MM, Rancourt D, Farrar GJ, Kenna P, Hazel M, Bush RA, Sieving PA, Sheils DM, McNally N, Creighton P, Erven A, Boros A, Gulya K, Capecchi MR, and Humphries P. Retinopathy induced in mice by targeted disruption of the rhodopsin gene. Nat Genet 15: 216-219, 1997[Web of Science][Medline]. |
| 101. |
Hwa J,
Reeves PJ,
Klein-Seetharaman J,
Davidson F, and Khorana HG.
Structure and function in rhodopsin: further elucidation of the role of the intradiscal cysteines, Cys-110, -185, and -187, in rhodopsin folding and function.
Proc Natl Acad Sci USA
96: 1932-1935, 1999 |
| 102. |
Imai H,
Kojima D,
Oura T,
Tachibanaki S,
Terakita A, and Shichida Y.
Single amino acid residue as a functional determinant of rod and cone visual pigments.
Proc Natl Acad Sci USA
94: 2322-2326, 1997 |
| 103. | Isele J, Sakmar TP, and Siebert F. Rhodopsin activation affects the environment of specific neighboring phospholipids: an FTIR study. Biophys J 79: 3063-3071, 2000[Web of Science][Medline]. |
| 104. | Jager F, Fahmy K, Sakmar TP, and Siebert F. Identification of glutamic acid 113 as the Schiff base proton acceptor in the metarhodopsin II photointermediate of rhodopsin. Biochemistry 33: 10878-10882, 1994[Medline]. |
| 105. | Jager F, Jager S, Krutle O, Friedman N, Sheves M, Hofmann KP, and Siebert F. Interactions of the beta-ionone ring with the protein in the visual pigment rhodopsin control the activation mechanism. An FTIR and fluorescence study on artificial vertebrate rhodopsins. Biochemistry 33: 7389-7397, 1994[Medline]. |
| 106. | Jager S, Han M, Lewis JW, Szundi I, Sakmar TP, and Kliger DS. Properties of early photolysis intermediates of rhodopsin are affected by glycine 121 and phenylalanine 261. Biochemistry 36: 11804-11810, 1997[Medline]. |
| 107. |
Jager S,
Lewis JW,
Zvyaga TA,
Szundi I,
Sakmar TP, and Kliger DS.
Chromophore structural changes in rhodopsin from nanoseconds to microseconds following pigment photolysis.
Proc Natl Acad Sci USA
94: 8557-8562, 1997 |
| 108. | Jager S, Lewis JW, Zvyaga TA, Szundi I, Sakmar TP, and Kliger DS. Time-resolved spectroscopy of the early photolysis intermediates of rhodopsin Schiff base counterion mutants. Biochemistry 36: 1999-2009, 1997[Medline]. |
| 109. | Jager S, Szundi I, Lewis JW, Mah TL, and Kliger DS. Effects of pH on rhodopsin photointermediates from lumirhodopsin to metarhodopsin II. Biochemistry 37: 6998-7005, 1998[Medline]. |
| 110. |
Ji TH,
Grossmann M, and Ji I.
G protein-coupled receptors. I. Diversity of receptor-ligand interactions.
J Biol Chem
273: 17299-17302, 1998 |
| 111. |
Karnik SS, and Khorana HG.
Assembly of functional rhodopsin requires a disulfide bond between cysteine residues 110 and 187.
J Biol Chem
265: 17520-17524, 1990 |
| 112. |
Karnik SS,
Sakmar TP,
Chen HB, and Khorana HG.
Cysteine residues 110 and 187 are essential for the formation of correct structure in bovine rhodopsin.
Proc Natl Acad Sci USA
85: 8459-8463, 1988 |
| 113. | Kaushal S, and Khorana HG. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa. Biochemistry 33: 6121-6128, 1994[Medline]. |
| 114. |
Kaushal S,
Ridge KD, and Khorana HG.
Structure and function in rhodopsin: the role of asparagine-linked glycosylation.
Proc Natl Acad Sci USA
91: 4024-4028, 1994 |
| 115. | Kawamura S. Calcium-dependent regulation of rhodopsin phosphorylation. Novartis Found Symp 224: 208-224, 1999[Medline]. |
| 116. |
Khorana HG.
Rhodopsin, photoreceptor of the rod cell. An emerging pattern for structure and function.
J Biol Chem
267: 1-4, 1992 |
| 117. | Kibelbek J, Mitchell DC, Beach JM, and Litman BJ. Functional equivalence of metarhodopsin II and the Gt-activating form of photolyzed bovine rhodopsin. Biochemistry 30: 6761-6768, 1991[Medline]. |
| 118. |
Kim JM,
Altenbach C,
Thurmond RL,
Khorana HG, and Hubbell WL.
Structure and function in rhodopsin: rhodopsin mutants with a neutral amino acid at E134 have a partially activated conformation in the dark state.
Proc Natl Acad Sci USA
94: 14273-14278, 1997 |
| 119. |
Kisselev OG,
Kao J,
Ponder JW,
Fann YC,
Gautam N, and Marshall GR.
Light-activated rhodopsin induces structural binding motif in G protein alpha subunit.
Proc Natl Acad Sci USA
95: 4270-4275, 1998 |
| 120. |
Kisselev OG,
Meyer CK,
Heck M,
Ernst OP, and Hofmann KP.
Signal transfer from rhodopsin to the G-protein: evidence for a two-site sequential fit mechanism.
Proc Natl Acad Sci USA
96: 4898-4903, 1999 |
| 121. |
Kjelsberg MA,
Cotecchia S,
Ostrowski J,
Caron MG, and Lefkowitz RJ.
Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation.
J Biol Chem
267: 1430-1433, 1992 |
| 122. |
Klein-Seetharaman J,
Getmanova EV,
Loewen MC,
Reeves PJ, and Khorana HG.
NMR spectroscopy in studies of light-induced structural changes in mammalian rhodopsin: applicability of solution (19)F NMR.
Proc Natl Acad Sci USA
96: 13744-13749, 1999 |
| 123. | Klein-Seetharaman J, Hwa J, Cai K, Altenbach C, Hubbell WL, and Khorana HG. Single-cysteine substitution mutants at amino acid positions 55-75, the sequence connecting the cytoplasmic ends of helices I and II in rhodopsin: reactivity of the sulfhydryl groups and their derivatives identifies a tertiary structure that changes upon light-activation. Biochemistry 38: 7938-7944, 1999[Medline]. |
| 124. | Kliger DS, and Lewis JW. Spectral and kinetic characterization of visual pigment photointermediates. Israel J Chem 35: 289-307, 1995. |
| 125. | Knox BE, Schlueter C, Sanger BM, Green CB, and Besharse JC. Transgene expression in Xenopus rods. FEBS Lett 423: 117-121, 1998[Web of Science][Medline]. |
| 126. | Kochendoerfer GG, Kaminaka S, and Mathies RA. Ultraviolet resonance Raman examination of the light-induced protein structural changes in rhodopsin activation. Biochemistry 36: 13153-13159, 1997[Medline]. |
| 127. | Kochendoerfer GG, Lin SW, Sakmar TP, and Mathies RA. How color visual pigments are tuned. Trends Biochem Sci 24: 300-305, 1999[Web of Science][Medline]. |
| 128. | Kochendoerfer GG, Verdegem PJ, van der Hoef I, Lugtenburg J, and Mathies RA. Retinal analog study of the role of steric interactions in the excited state isomerization dynamics of rhodopsin. Biochemistry 35: 16230-16240, 1996[Medline]. |
| 129. |
Konig B,
Arendt A,
McDowell JH,
Kahlert M,
Hargrave PA, and Hofmann KP.
Three cytoplasmic loops of rhodopsin interact with transducin.
Proc Natl Acad Sci USA
86: 6878-6882, 1989 |
| 130. | Kraulis PJ. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structure. J Appl Crystallogr 24: 946-950, 1991. |
| 131. | Krebs A, Villa C, Edwards PC, and Schertler GF. Characterisation of an improved two-dimensional p22121 crystal from bovine rhodopsin. J Mol Biol 282: 991-1003, 1998[Web of Science][Medline]. |
| 132. | Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, and Morikawa K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407: 971-977, 2000[Medline]. |
| 133. | Lagnado L, and Baylor DA. Calcium controls light-triggered formation of catalytically active rhodopsin. Nature 367: 273-277, 1994[Medline]. |
| 134. |
Lamb TD.
Gain and kinetics of activation in the G-protein cascade of phototransduction.
Proc Natl Acad Sci USA
93: 566-570, 1996 |
| 135. | Langen R, Cai K, Altenbach C, Khorana HG, and Hubbell WL. Structural features of the C-terminal domain of bovine rhodopsin: a site-directed spin-labeling study. Biochemistry 38: 7918-7924, 1999[Medline]. |
| 136. |
LaVail MM,
Yasumura D,
Matthes MT,
Lau-Villacorta C,
Unoki K,
Sung CH, and Steinberg RH.
Protection of mouse photoreceptors by survival factors in retinal degenerations.
Invest Ophthalmol Vis Sci
39: 592-602, 1998 |
| 137. |
Le Gouill C,
Parent JL,
Rola-Pleszczynski M, and Stankova J.
Structural and functional requirements for agonist-induced internalization of the human platelet-activating factor receptor.
J Biol Chem
272: 21289-21295, 1997 |
| 138. |
Lem J,
Krasnoperova NV,
Calvert PD,
Kosaras B,
Cameron DA,
Nicolo M,
Makino CL, and Sidman RL.
Morphological, physiological, and biochemical changes in rhodopsin knockout mice.
Proc Natl Acad Sci USA
96: 736-741, 1999 |
| 139. | Lem J, and Makino CL. Phototransduction in transgenic mice. Curr Opin Neurobiol 6: 453-458, 1996[Web of Science][Medline]. |
| 140. | Lewis JW, Jager S, and Kliger DS. Absorbance changes by aromatic amino acid side chains in early rhodopsin photointermediates. Photochem Photobiol 66: 741-746, 1997[Web of Science][Medline]. |
| 141. | Lewis JW, and Kliger DS. Absorption spectroscopy in studies of visual pigments: spectral and kinetic characterization of intermediates. Methods Enzymol 315: 164-178, 2000[Web of Science][Medline]. |
| 142. | Lewis JW, Szundi I, and Kliger DS. Structural constraints imposed by a non-native disulfide cause reversible changes in rhodopsin photointermediate kinetics. Biochemistry 39: 7851-7855, 2000[Medline]. |
| 143. |
Li T,
Franson WK,
Gordon JW,
Berson EL, and Dryja TP.
Constitutive activation of phototransduction by K296E opsin is not a cause of photoreceptor degeneration.
Proc Natl Acad Sci USA
92: 3551-3555, 1995 |
| 144. |
Li T,
Sandberg MA,
Pawlyk BS,
Rosner B,
Hayes KC,
Dryja TP, and Berson EL.
Effect of vitamin A supplementation on rhodopsin mutants threonine-17 methionine and proline-347 serine in transgenic mice and in cell cultures.
Proc Natl Acad Sci USA
95: 11933-11938, 1998 |
| 145. |
Li T,
Snyder WK,
Olsson JE, and Dryja TP.
Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments.
Proc Natl Acad Sci USA
93: 14176-14181, 1996 |
| 146. |
Li ZY,
Wong F,
Chang JH,
Possin DE,
Hao Y,
Petters RM, and Milam AH.
Rhodopsin transgenic pigs as a model for human retinitis pigmentosa.
Invest Ophthalmol Vis Sci
39: 808-819, 1998 |
| 147. | Lin SW, Han M, and Sakmar TP. Analysis of functional microdomains of rhodopsin. Methods Enzymol 315: 116-130, 2000[Web of Science][Medline]. |
| 148. |
Lin SW,
Kochendoerfer GG,
Carroll KS,
Wang D,
Mathies RA, and Sakmar TP.
Mechanisms of spectral tuning in blue cone visual pigments. Visible and Raman spectroscopy of blue-shifted rhodopsin mutants.
J Biol Chem
273: 24583-24591, 1998 |
| 149. | Lin SW, and Sakmar TP. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 35: 11149-11159, 1996[Medline]. |
| 150. | Lin SW, and Sakmar TP. Colour tuning mechanisms of visual pigments. Novartis Found Symp 224: 124-141, 1999[Medline]. |
| 151. | Lin SW, Sakmar TP, Franke RR, Khorana HG, and Mathies RA. Resonance Raman microprobe spectroscopy of rhodopsin mutants: effect of substitutions in the third transmembrane helix. Biochemistry 31: 5105-5111, 1992[Medline]. |
| 152. |
Liu C,
Li Y,
Peng M,
Laties AM, and Wen R.
Activation of caspase-3 in the retina of transgenic rats with the rhodopsin mutation Ser334ter during photoreceptor degeneration.
J Neurosci
19: 4778-4785, 1999 |
| 153. |
Longstaff C,
Calhoon RD, and Rando RR.
Deprotonation of the Schiff base of rhodopsin is obligate in the activation of the G protein.
Proc Natl Acad Sci USA
83: 4209-4213, 1986 |
| 154. | Lou J, Tan Q, Karnaukhova E, Berova N, Nakanishi K, and Crouch RK. Synthetic retinals: convenient probes of rhodopsin and visual transduction process. Methods Enzymol 315: 219-237, 2000[Web of Science][Medline]. |
| 155. |
Marin EP,
Krishna AG,
Zvyaga TA,
Isele J,
Siebert F, and Sakmar TP.
The amino terminus of the fourth cytoplasmic loop of rhodopsin modulates rhodopsin-transducin interaction.
J Biol Chem
275: 1930-1936, 2000 |
| 156. |
Martinez-Gimeno M,
Trujillo MJ,
Lorda I,
Gimenez A,
Calvo MT,
Ayuso C, and Carballo M.
Three novel mutations (P215L, T289P, and 3811-2 A G) in the rhodopsin gene in autosomal dominant retinitis pigmentosa in Spanish families.
Hum Mutat
16: 95-96, 2000[Medline].
|
| 157. | McDowell JH, Nawrocki JP, and Hargrave PA. Phosphorylation sites in bovine rhodopsin. Biochemistry 32: 4968-4974, 1993[Medline]. |
| 158. |
McNally N,
Kenna P,
Humphries MM,
Hobson AH,
Khan NW,
Bush RA,
Sieving PA,
Humphries P, and Farrar GJ.
Structural and functional rescue of murine rod photoreceptors by human rhodopsin transgene.
Hum Mol Genet
8: 1309-1312, 1999 |
| 159. | Melia TJ Jr, Cowan CW, Angleson JK, and Wensel TG. A comparison of the efficiency of G protein activation by ligand-free and light-activated forms of rhodopsin. Biophys J 73: 3182-3191, 1997[Web of Science][Medline]. |
| 160. | Merbs SL, and Nathans J. Absorption spectra of human cone pigments. Nature 356: 433-435, 1992[Medline]. |
| 161. |
Merbs SL, and Nathans J.
Absorption spectra of the hybrid pigments responsible for anomalous color vision.
Science
258: 464-466, 1992 |
| 162. |
Milburn MV,
Prive GG,
Milligan DL,
Scott WG,
Yeh J,
Jancarik J,
Koshland DE Jr, and Kim SH.
Three-dimensional structures of the ligand-binding domain of the bacterial aspartate receptor with and without a ligand.
Science
254: 1342-1347, 1991 |
| 163. | Milla E, Heon E, Grounauer PA, Piguet B, Ducrey N, Stone EM, Schorderet DF, and Munier FL. Rhodopsin C110Y mutation causes a type 2 autosomal dominant retinitis pigmentosa. Ophthal Genet 19: 131-139, 1998[Web of Science][Medline]. |
| 164. |
Min KC,
Zvyaga TA,
Cypess AM, and Sakmar TP.
Characterization of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Mutations on the cytoplasmic surface affect transducin activation.
J Biol Chem
268: 9400-9404, 1993 |
| 165. |
Naash MI,
Hollyfield JG,
al-Ubaidi MR, and Baehr W.
Simulation of human autosomal dominant retinitis pigmentosa in transgenic mice expressing a mutated murine opsin gene.
Proc Natl Acad Sci USA
90: 5499-5503, 1993 |
| 166. |
Naash MI,
Ripps H,
Li S,
Goto Y, and Peachey NS.
Polygenic disease and retinitis pigmentosa: albinism exacerbates photoreceptor degeneration induced by the expression of a mutant opsin in transgenic mice.
J Neurosci
16: 7853-7858, 1996 |
| 167. |
Naash ML,
Peachey NS,
Li ZY,
Gryczan CC,
Goto Y,
Blanks J,
Milam AH, and Ripps H.
Light-induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin.
Invest Ophthalmol Vis Sci
37: 775-782, 1996 |
| 168. | Nagata T, Terakita A, Kandori H, Kojima D, Shichida Y, and Maeda A. Water and peptide backbone structure in the active center of bovine rhodopsin. Biochemistry 36: 6164-6170, 1997[Medline]. |
| 169. |
Nakayama TA, and Khorana HG.
Mapping of the amino acids in membrane-embedded helices that interact with the retinal chromophore in bovine rhodopsin.
J Biol Chem
266: 4269-4275, 1991 |
| 170. |
Nakayama TA, and Khorana HG.
Orientation of retinal in bovine rhodopsin determined by cross-linking using a photoactivatable analog of 11-cis-retinal.
J Biol Chem
265: 15762-15769, 1990 |
| 171. | Nathans J. Determinants of visual pigment absorbance: role of charged amino acids in the putative transmembrane segments. Biochemistry 29: 937-942, 1990[Medline]. |
| 172. | Nathans J. Rhodopsin: structure, function, and genetics. Biochemistry 31: 4923-4931, 1992[Medline]. |
| 173. |
Nathans J,
Davenport CM,
Maumenee IH,
Lewis RA,
Hejtmancik JF,
Litt M,
Lovrien E,
Weleber R,
Bachynski B,
Zwas F,
Klingaman R, and Fishman G.
Molecular genetics of human blue cone monochromacy.
Science
245: 831-838, 1989 |
| 174. | Nathans J, and Hogness DS. Isolation, sequence analysis, and intron-exon arrangement of the gene encoding bovine rhodopsin. Cell 34: 807-814, 1983[Web of Science][Medline]. |
| 175. |
Nathans J, and Hogness DS.
Isolation and nucleotide sequence of the gene encoding human rhodopsin.
Proc Natl Acad Sci USA
81: 4851-4855, 1984 |
| 176. |
Nathans J,
Piantanida TP,
Eddy RL,
Shows TB, and Hogness DS.
Molecular genetics of inherited variation in human color vision.
Science
232: 203-210, 1986 |
| 177. |
Nathans J,
Thomas D, and Hogness DS.
Molecular genetics of human color vision: the genes encoding blue, green, and red pigments.
Science
232: 193-202, 1986 |
| 178. | Neitz J, and Neitz M. In: Molecular Genetics of Inherited Eye Disorders, edited by Wright AF, and Jay B. Chur, Switzerland: Harwood Academic, 1994, p. 217. |
| 179. | Neitz J, Neitz M, and Jacobs GH. Analysis of fusion gene and encoded photopigment of colour-blind humans. Nature 342: 679-682, 1989[Medline]. |
| 180. |
Neitz M, and Neitz J.
Numbers and ratios of visual pigment genes for normal red-green color vision.
Science
267: 1013-1016, 1995 |
| 181. |
Neitz M,
Neitz J, and Jacobs GH.
Spectral tuning of pigments underlying red-green color vision.
Science
252: 971-974, 1991 |
| 182. | Nishikawa S, and LaVail MM. Neovascularization of the RPE: temporal differences in mice with rod photoreceptor gene defects. Exp Eye Res 67: 509-515, 1998[Web of Science][Medline]. |
| 183. | Nishimura S, Kandori H, and Maeda A. Interaction between photoactivated rhodopsin and the C-terminal peptide of transducin alpha-subunit studied by FTIR spectroscopy. Biochemistry 37: 15816-15824, 1998[Medline]. |
| 184. | Ohguro H, Palczewski K, Ericsson LH, Walsh KA, and Johnson RS. Sequential phosphorylation of rhodopsin at multiple sites. Biochemistry 32: 5718-5724, 1993[Medline]. |
| 185. |
Ohguro H,
Rudnicka-Nawrot M,
Buczylko J,
Zhao X,
Taylor JA,
Walsh KA, and Palczewski K.
Structural and enzymatic aspects of rhodopsin phosphorylation.
J Biol Chem
271: 5215-5224, 1996 |
| 186. | Okada T, Le Trong I, Fox BA, Behnke CA, Stenkamp RE, and Palczewski K. X-ray diffraction analysis of three-dimensional crystals of bovine rhodopsin obtained from mixed micelles. J Struct Biol 130: 73-80, 2000[Web of Science][Medline]. |
| 187. | Okada T, Takeda K, and Kouyama T. Highly selective separation of rhodopsin from bovine rod outer segment membranes using combination of divalent cation and alkyl(thio)glucoside. Photochem Photobiol 67: 495-499, 1998[Web of Science][Medline]. |
| 188. | Olsson JE, Gordon JW, Pawlyk BS, Roof D, Hayes A, Molday RS, Mukai S, Cowley GS, Berson EL, and Dryja TP. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 9: 815-830, 1992[Web of Science][Medline]. |
| 189. | Oprian DD. The ligand-binding domain of rhodopsin and other G protein-linked receptors. J Bioenerg Biomembr 24: 211-217, 1992[Web of Science][Medline]. |
| 190. | Oprian DD, Asenjo AB, Lee N, and Pelletier SL. Design, chemical synthesis, and expression of genes for the three human color vision pigments. Biochemistry 30: 11367-11372, 1991[Medline]. |
| 191. | Osawa S, and Weiss ER. The carboxyl terminus of bovine rhodopsin is not required for G protein activation. Mol Pharmacol 46: 1036-1040, 1994[Abstract]. |
| 192. | Oseroff AR, and Callender RH. Resonance Raman spectroscopy of rhodopsin in retinal disk membranes. Biochemistry 13: 4243-4248, 1974[Medline]. |
| 193. | Ovchinnikov UYA. Rhodopsin and bacteriorhodopsin: structure-function relationships. FEBS Lett 148: 179-191, 1982[Web of Science][Medline]. |
| 194. |
Palczewski K,
Kumasaka T,
Hori T,
Behnke CA,
Motoshima H,
Fox BA,
Le Trong I,
Teller DC,
Okada T,
Stenkamp RE,
Yamamoto M, and Miyano M.
Crystal structure of rhodopsin: a G protein-coupled receptor.
Science
289: 739-745, 2000 |
| 195. | Palczewski K, Van Hooser JP, Garwin GG, Chen J, Liou GI, and Saari JC. Kinetics of visual pigment regeneration in excised mouse eyes and in mice with a targeted disruption of the gene encoding interphotoreceptor retinoid-binding protein or arrestin. Biochemistry 38: 12012-12019, 1999[Medline]. |
| 196. | Palings I, Pardoen JA, van den Berg E, Winkel C, Lugtenburg J, and Mathies RA. Assignment of fingerprint vibrations in the resonance Raman spectra of rhodopsin, isorhodopsin, and bathorhodopsin: implications for chromophore structure and environment. Biochemistry 26: 2544-2556, 1987[Medline]. |
| 197. | Pannarale MR, Grammatico B, Iannaccone A, Forte R, DeBernardo C, Flagiello L, Vingolo EM, and Del Porto G. Autosomal-dominant retinitis pigmentosa associated with an Arg-135-Trp point mutation of the rhodopsin gene. Clinical features and longitudinal observations. Ophthalmology 103: 1443-1452, 1996[Web of Science][Medline]. |
| 198. | Papac DI, Oatis JE Jr, Crouch RK, and Knapp DR. Mass spectrometric identification of phosphorylation sites in bleached bovine rhodopsin. Biochemistry 32: 5930-5934, 1993[Medline]. |
| 199. | Papermaster DS. Preparation of retinal rod outer segments. Methods Enzymol 81: 48-52, 1982[Web of Science][Medline]. |
| 200. | Petters RM, Alexander CA, Wells KD, Collins EB, Sommer JR, Blanton MR, Rojas G, Hao Y, Flowers WL, Banin E, Cideciyan AV, Jacobson SG, and Wong F. Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa. Nat Biotechnol 15: 965-970, 1997[Web of Science][Medline]. |
| 201. |
Phillips WJ,
Wong SC, and Cerione RA.
Rhodopsin/transducin interactions. II. Influence of the transducin-beta gamma subunit complex on the coupling of the transducin-alpha subunit to rhodopsin.
J Biol Chem
267: 17040-17046, 1992 |
| 202. | Ponjavic V, Abrahamson M, Andreasson S, Ehinger B, Fex G, and Polland W. A mild phenotype of autosomal dominant retinitis pigmentosa is associated with the rhodopsin mutation Pro-267-Leu. Ophthal Genet 18: 63-70, 1997[Web of Science][Medline]. |
| 203. |
Popp A,
Ujj L, and Atkinson GH.
Bathorhodopsin structure in the room-temperature rhodopsin photosequence: picosecond time-resolved coherent anti-Stokes Raman scattering.
Proc Natl Acad Sci USA
93: 372-376, 1996 |
| 204. | Probst WC, Snyder LA, Schuster DI, Brosius J, and Sealfon SC. Sequence alignment of the G-protein coupled receptor superfamily. DNA Cell Biol 11: 1-20, 1992[Web of Science][Medline]. |
| 205. | Rafferty CN, Muellenberg CG, and Shichi H. Tryptophan in bovine rhodopsin: its content, spectral properties and environment. Biochemistry 19: 2145-2151, 1980[Medline]. |
| 206. | Rando RR. Polyenes and vision. Chem Biol 3: 255-262, 1996[Web of Science][Medline]. |
| 207. | Rao VR, Cohen GB, and Oprian DD. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 367: 639-642, 1994[Medline]. |
| 208. | Rao VR, and Oprian DD. Activating mutations of rhodopsin and other G protein-coupled receptors. Annu Rev Biophys Biomol Struct 25: 287-314, 1996[Web of Science][Medline]. |
| 209. | Rath P, DeCaluwe LL, Bovee-Geurts PH, DeGrip WJ, and Rothschild KJ. Fourier transform infrared difference spectroscopy of rhodopsin mutants: light activation of rhodopsin causes hydrogen-bonding change in residue aspartic acid-83 during meta II formation. Biochemistry 32: 10277-10282, 1993[Medline]. |
| 210. | Rath P, DeGrip WJ, and Rothschild KJ. Photoactivation of rhodopsin causes an increased hydrogen-deuterium exchange of buried peptide groups. Biophys J 74: 192-198, 1998[Web of Science][Medline]. |
| 211. | Resek JF, Farahbakhsh ZT, Hubbell WL, and Khorana HG. Formation of the meta II photointermediate is accompanied by conformational changes in the cytoplasmic surface of rhodopsin. Biochemistry 32: 12025-12032, 1993[Medline]. |
| 212. |
Ridge KD,
Bhattacharya S,
Nakayama TA, and Khorana HG.
Light-stable rhodopsin. II. An opsin mutant (TRP-265-Phe) and a retinal analog with a nonisomerizable 11-cis configuration form a photostable chromophore.
J Biol Chem
267: 6770-6775, 1992 |
| 213. | Ridge KD, Lu Z, Liu X, and Khorana HG. Structure and function in rhodopsin. Separation and characterization of the correctly folded and misfolded opsins produced on expression of an opsin mutant gene containing only the native intradiscal cysteine codons. Biochemistry 34: 3261-3267, 1995[Medline]. |
| 214. | Ripps H, Peachey NS, Xu X, Nozell SE, Smith SB, and Liou GI. The rhodopsin cycle is preserved in IRBP "knockout" mice despite abnormalities in retinal structure and function. Vis Neurosci 17: 97-105, 2000[Web of Science][Medline]. |
| 215. | Robinson PR, Cohen GB, Zhukovsky EA, and Oprian DD. Constitutively active mutants of rhodopsin. Neuron 9: 719-725, 1992[Web of Science][Medline]. |
| 216. | Rodbell M. The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature 284: 17-22, 1980[Medline]. |
| 217. |
Roof DJ,
Adamian M, and Hayes A.
Rhodopsin accumulation at abnormal sites in retinas of mice with a human P23H rhodopsin transgene.
Invest Ophthalmol Vis Sci
35: 4049-4062, 1994 |
| 218. | Rothschild KJ. FTIR difference spectroscopy of bacteriorhodopsin: toward a molecular model. J Bioenerg Biomembr 24: 147-167, 1992[Web of Science][Medline]. |
| 219. |
Saari JC.
Biochemistry of visual pigment regeneration: the Friedenwald lecture.
Invest Ophthalmol Vis Sci
41: 337-348, 2000 |
| 220. | Sachs K, Maretzki D, and Hofmann KP. Assays for activation of opsin by all-trans-retinal. Methods Enzymol 315: 238-251, 2000[Web of Science][Medline]. |
| 221. | Sakmar TP. In: Handbook of Receptors and Channels: G Protein-Coupled Receptors, edited by Peroutka SJ. Boca Raton, FL: CRC, 1994, p. 257. |
| 222. | Sakmar TP. Rhodopsin: a prototypical G protein-coupled receptor. Prog Nucleic Acid Res Mol Biol 59: 1-34, 1998[Web of Science][Medline]. |
| 223. | Sakmar TP. Rhodopsin early receptor potential revisited. Biophys J 77: 1189-1191, 1999[Web of Science][Medline]. |
| 224. | Sakmar TP, and Fahmy K. Properties and photoactivity of rhodopsin mutants. Israel J Chem 35: 325-337, 1995. |
| 225. |
Sakmar TP,
Franke RR, and Khorana HG.
Glutamic acid-113 serves as the retinylidene Schiff base counterion in bovine rhodopsin.
Proc Natl Acad Sci USA
86: 8309-8313, 1989 |
| 226. | Sanchez B, Borreo S, Chaparro P, Rueda T, Lopez F, and Antinolo G. A novel null mutation in the rhodopsin gene causing late onset autosomal dominant retinitis pigmentosa. Hum Mutat 7: 180, 1996. |
| 227. | Schertler GF, Villa C, and Henderson R. Projection structure of rhodopsin. Nature 362: 770-772, 1993[Medline]. |
| 228. | Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, and Bourne HR. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature 383: 347-350, 1996[Medline]. |
| 229. | Siebert F. Applications of FTIR spectroscopy to the investigation of dark structures and photoreactions of visual pigments. Israel J Chem 35: 309-323, 1995. |
| 230. |
Sieving PA,
Richards JE,
Naarendorp F,
Bingham EL,
Scott K, and Alpern M.
Dark-light: model for nightblindness from the human rhodopsin Gly-90 Asp mutation.
Proc Natl Acad Sci USA
92: 880-884, 1995 |
| 231. | Spiegel AM. Defects in G protein-coupled signal transduction in human disease. Annu Rev Physiol 58: 143-170, 1996[Web of Science][Medline]. |
| 232. | Strader CD, Fong TM, Tota MR, Underwood D, and Dixon RA. Structure and function of G protein-coupled receptors. Annu Rev Biochem 63: 101-132, 1994[Web of Science][Medline]. |
| 233. | Streichert LC, Birnbach CD, and Reh TA. A diffusible factor from normal retinal cells promotes rod photoreceptor survival in an in vitro model of retinitis pigmentosa. J Neurobiol 39: 475-490, 1999[Web of Science][Medline]. |
| 234. | Struthers M, Yu H, Kono M, and Oprian DD. Tertiary interactions between the fifth and sixth transmembrane segments of rhodopsin. Biochemistry 38: 6597-6603, 1999[Medline]. |
| 235. | Struthers M, Yu H, and Oprian DD. G protein-coupled receptor activation: analysis of a highly constrained, "straitjacketed" rhodopsin. Biochemistry 39: 7938-7942, 2000[Medline]. |
| 236. |
Stryer L.
Visual excitation and recovery.
J Biol Chem
266: 10711-10714, 1991 |
| 237. | Subramaniam S, Gerstein M, Oesterhelt D, and Henderson R. Electron diffraction analysis of structural changes in the photocycle of bacteriorhodopsin. EMBO J 12: 1-8, 1993[Web of Science][Medline]. |
| 238. | Subramaniam S, and Henderson R. Molecular mechanism of vectorial proton translocation by bacteriorhodopsin. Nature 406: 653-657, 2000[Medline]. |
| 239. | Subramaniam S, Lindahl M, Bullough P, Faruqi AR, Tittor J, Oesterhelt D, Brown L, Lanyi J, and Henderson R. Protein conformational changes in the bacteriorhodopsin photocycle. J Mol Biol 287: 145-161, 1999[Web of Science][Medline]. |
| 240. | Sullivan JM, and Shukla P. Time-resolved rhodopsin activation currents in a unicellular expression system. Biophys J 77: 1333-1357, 1999[Web of Science][Medline]. |
| 241. |
Sung CH,
Davenport CM,
Hennessey JC,
Maumenee IH,
Jacobson SG,
Heckenlively JR,
Nowakowski R,
Fishman G,
Gouras P, and Nathans J.
Rhodopsin mutations in autosomal dominant retinitis pigmentosa.
Proc Natl Acad Sci USA
88: 6481-6485, 1991 |
| 242. | Sung CH, Makino C, Baylor D, and Nathans J. A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment. J Neurosci 14: 5818-5833, 1994[Abstract]. |
| 243. |
Sung CH,
Schneider BG,
Agarwal N,
Papermaster DS, and Nathans J.
Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa.
Proc Natl Acad Sci USA
88: 8840-8844, 1991 |
| 244. |
Surya A,
Foster KW, and Knox BE.
Transducin activation by the bovine opsin apoprotein.
J Biol Chem
270: 5024-5031, 1995 |
| 245. | Surya A, Stadel JM, and Knox BE. Evidence for multiple, biochemically distinguishable states in the G protein-coupled receptor, rhodopsin. Trends Pharmacol Sci 19: 243-247, 1998[Medline]. |
| 246. | Tai AW, Chuang JZ, Bode C, Wolfrum U, and Sung CH. Rhodopsin's carboxy-terminal cytoplasmic tail acts as a membrane receptor for cytoplasmic dynein by binding to the dynein light chain Tctex-1. Cell 97: 877-887, 1999[Web of Science][Medline]. |
| 247. | Takemoto DJ, Morrison D, Davis LC, and Takemoto LJ. C-terminal peptides of rhodopsin. Determination of the optimum sequence for recognition of retinal transducin. Biochem J 235: 309-312, 1986[Web of Science][Medline]. |
| 248. | Tso MO, Li WW, Zhang C, Lam TT, Hao Y, Petters RM, and Wong F. A pathologic study of degeneration of the rod and cone populations of the rhodopsin Pro347Leu transgenic pigs. Trans Am Ophthalmol Soc 95: 467-483, 1997[Medline]. |
| 249. | Unger VM, Hargrave PA, Baldwin JM, and Schertler GF. Arrangement of rhodopsin transmembrane alpha-helices. Nature 389: 203-206, 1997[Medline]. |
| 250. |
Unson CG,
Wu CR,
Sakmar TP, and Merrifield RB.
Selective stabilization of the high affinity binding conformation of glucagon receptor by the long splice variant of Galpha(s).
J Biol Chem
275: 21631-21638, 2000 |
| 251. | Verdegem PJ, Bovee-Geurts PH, de Grip WJ, Lugtenburg J, and de Groot HJ. Retinylidene ligand structure in bovine rhodopsin, metarhodopsin-I, and 10-methylrhodopsin from internuclear distance measurements using 13C-labeling and 1-D rotational resonance MAS NMR. Biochemistry 38: 11316-11324, 1999[Medline]. |
| 252. |
Wald G.
Molecular basis of visual excitation.
Science
162: 230-239, 1968 |
| 253. | Wald G. The molecular basis of visual excitation. Nature 219: 800-807, 1968[Medline]. |
| 254. | Wang M, Lam TT, Tso MO, and Naash MI. Expression of a mutant opsin gene increases the susceptibility of the retina to light damage. Vis Neurosci 14: 55-62, 1997[Web of Science][Medline]. |
| 255. |
Wang Q,
Schoenlein RW,
Peteanu LA,
Mathies RA, and Shank CV.
Vibrationally coherent photochemistry in the femtosecond primary event of vision.
Science
266: 422-424, 1994 |
| 256. | Wang Y, Macke JP, Merbs SL, Zack DJ, Klaunberg B, Bennett J, Gearhart J, and Nathans J. A locus control region adjacent to the human red and green visual pigment genes. Neuron 9: 429-440, 1992[Web of Science][Medline]. |
| 257. |
Wang Z,
Asenjo AB, and Oprian DD.
Identification of the Cl -binding site in the human red and green color vision pigments.
Biochemistry
32: 2125-2130, 1993[Medline].
|
| 258. | Weiss ER, Hao Y, Dickerson CD, Osawa S, Shi W, Zhang L, and Wong F. Altered cAMP levels in retinas from transgenic mice expressing a rhodopsin mutant. Biochem Biophys Res Commun 216: 755-761, 1995[Web of Science][Medline]. |
| 259. | Weiss ER, Osawa S, Shi W, and Dickerson CD. Effects of carboxyl-terminal truncation on the stability and G protein-coupling activity of bovine rhodopsin. Biochemistry 33: 7587-7593, 1994[Medline]. |
| 260. | Wu TH, Ting TD, Okajima TI, Pepperberg DR, Ho YK, Ripps H, and Naash MI. Opsin localization and rhodopsin photochemistry in a transgenic mouse model of retinitis pigmentosa. Neuroscience 87: 709-717, 1998[Web of Science][Medline]. |
| 261. |
Yamashita T,
Terakita A, and Shichida Y.
Distinct roles of the second and the third cytoplasmic loops of bovine rhodopsin in G protein activation.
J Biol Chem
275: 34272-34279, 2000 |
| 262. | Yau KW, Matthews G, and Baylor DA. Thermal activation of the visual transduction mechanism in retinal rods. Nature 279: 806-807, 1979[Medline]. |
| 263. | Yoshizawa T, and Wald G. Pre-lumirhodopsin and the bleaching of visual pigments. Nature 197: 1279-1286, 1963[Medline]. |
| 264. | Yu H, Kono M, and Oprian DD. State-dependent disulfide cross-linking in rhodopsin. Biochemistry 38: 12028-12032, 1999[Medline]. |
| 265. | Yu H, and Oprian DD. Tertiary interactions between transmembrane segments 3 and 5 near the cytoplasmic side of rhodopsin. Biochemistry 38: 12033-12040, 1999[Medline]. |
| 266. | Zhang H, Lerro KA, Yamamoto T, Lien TH, Sastry L, Gawinowicz MA, and Nakanishi K. The location of the chromophore in rhodopsin: a photoaffinity study. J Am Chem Soc 116: 10165-10173, 1994. |
| 267. |
Zhukovsky EA, and Oprian DD.
Effect of carboxylic acid side chains on the absorption maximum of visual pigments.
Science
246: 928-930, 1989 |
| 268. |
Zhukovsky EA,
Robinson PR, and Oprian DD.
Transducin activation by rhodopsin without a covalent bond to the 11-cis-retinal chromophore.
Science
251: 558-560, 1991 |
| 269. | Zvyaga TA, Fahmy K, Siebert F, and Sakmar TP. Characterization of the mutant visual pigment responsible for congenital night blindness: a biochemical and Fourier-transform infrared spectroscopy study. Biochemistry 35: 7536-7545, 1996[Medline]. |
This article has been cited by other articles:
![]() |
I. A. Balabin, W. Yang, and D. N. Beratan Coarse-grained modeling of allosteric regulation in protein receptors PNAS, August 25, 2009; 106(34): 14253 - 14258. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Lim, S. P. Yip, S. C. Cheung, K. W. Leung, S. T. S. Lam, and C. H. To Novel PRPF31 and PRPH2 Mutations and Co-occurrence of PRPF31 and RHO Mutations in Chinese Patients With Retinitis Pigmentosa Arch Ophthalmol, June 1, 2009; 127(6): 784 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ahuja, E. Crocker, M. Eilers, V. Hornak, A. Hirshfeld, M. Ziliox, N. Syrett, P. J. Reeves, H. G. Khorana, M. Sheves, et al. Location of the Retinal Chromophore in the Activated State of Rhodopsin* J. Biol. Chem., April 10, 2009; 284(15): 10190 - 10201. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mustafi and K. Palczewski Topology of Class A G Protein-Coupled Receptors: Insights Gained from Crystal Structures of Rhodopsins, Adrenergic and Adenosine Receptors Mol. Pharmacol., January 1, 2009; 75(1): 1 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mahalingam, K. Martinez-Mayorga, M. F. Brown, and R. Vogel Two protonation switches control rhodopsin activation in membranes PNAS, November 18, 2008; 105(46): 17795 - 17800. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Oliveira, C. M. Costa-Neto, C. R. Nakaie, S. Schreier, S. I. Shimuta, and A. C. M. Paiva The Angiotensin II AT1 Receptor Structure-Activity Correlations in the Light of Rhodopsin Structure Physiol Rev, April 1, 2007; 87(2): 565 - 592. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Abaffy, A. Malhotra, and C. W. Luetje The Molecular Basis for Ligand Specificity in a Mouse Olfactory Receptor: A NETWORK OF FUNCTIONALLY IMPORTANT RESIDUES J. Biol. Chem., January 12, 2007; 282(2): 1216 - 1224. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. D. Santos, L. A. Gardner, S. W. White, and S. W. Bahouth Characterization of the Residues in Helix 8 of the Human beta1-Adrenergic Receptor That Are Involved in Coupling the Receptor to G Proteins J. Biol. Chem., May 5, 2006; 281(18): 12896 - 12907. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Terada, N. Ohno, H. Ohguro, Z. Li, and S. Ohno Immunohistochemical Detection of Phosphorylated Rhodopsin in Light-exposed Retina of Living Mouse with In Vivo Cryotechnique J. Histochem. Cytochem., April 1, 2006; 54(4): 479 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Wang, X.-H. Wen, Z. Ablonczy, R. K. Crouch, C. L. Makino, and J. Lem Enhanced Shutoff of Phototransduction in Transgenic Mice Expressing Palmitoylation-deficient Rhodopsin J. Biol. Chem., July 1, 2005; 280(26): 24293 - 24300. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Perez and S. S. Karnik Multiple Signaling States of G-Protein-Coupled Receptors Pharmacol. Rev., June 1, 2005; 57(2): 147 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tsukamoto, A. Terakita, and Y. Shichida A rhodopsin exhibiting binding ability to agonist all-trans-retinal PNAS, May 3, 2005; 102(18): 6303 - 6308. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chinen, Y. Matsumoto, and S. Kawamura Reconstitution of Ancestral Green Visual Pigments of Zebrafish and Molecular Mechanism of Their Spectral Differentiation Mol. Biol. Evol., April 1, 2005; 22(4): 1001 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chinen, Y. Matsumoto, and S. Kawamura Spectral Differentiation of Blue Opsins between Phylogenetically Close but Ecologically Distant Goldfish and Zebrafish J. Biol. Chem., March 11, 2005; 280(10): 9460 - 9466. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhu, G.-F. Jang, B. Jastrzebska, S. Filipek, S. E. Pearce-Kelling, G. D. Aguirre, R. E. Stenkamp, G. M. Acland, and K. Palczewski A Naturally Occurring Mutation of the Opsin Gene (T4R) in Dogs Affects Glycosylation and Stability of the G Protein-coupled Receptor J. Biol. Chem., December 17, 2004; 279(51): 53828 - 53839. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ritter, K. Zimmermann, M. Heck, K. P. Hofmann, and F. J. Bartl Transition of Rhodopsin into the Active Metarhodopsin II State Opens a New Light-induced Pathway Linked to Schiff Base Isomerization J. Biol. Chem., November 12, 2004; 279(46): 48102 - 48111. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zimmermann, E. Ritter, F. J. Bartl, K. P. Hofmann, and M. Heck Interaction with Transducin Depletes Metarhodopsin III: A REGULATED RETINAL STORAGE IN VISUAL SIGNAL TRANSDUCTION? J. Biol. Chem., November 12, 2004; 279(46): 48112 - 48119. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Chan, A. Bradley, T. G. Wensel, and J. H. Wilson Knock-in human rhodopsin-GFP fusions as mouse models for human disease and targets for gene therapy PNAS, June 15, 2004; 101(24): 9109 - 9114. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Herrmann, M. Heck, P. Henklein, P. Henklein, C. Kleuss, K. P. Hofmann, and O. P. Ernst Sequence of Interactions in Receptor-G Protein Coupling J. Biol. Chem., June 4, 2004; 279(23): 24283 - 24290. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Shi and J. A. Javitch The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice PNAS, January 13, 2004; 101(2): 440 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Krebs, P. C. Edwards, C. Villa, J. Li, and G. F. X. Schertler The Three-dimensional Structure of Bovine Rhodopsin Determined by Electron Cryomicroscopy J. Biol. Chem., December 12, 2003; 278(50): 50217 - 50225. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Knox, E. Salcedo, K. Mathiesz, J. Schaefer, W.-H. Chou, L. V. Chadwell, W. C. Smith, S. G. Britt, and R. B. Barlow Heterologous Expression of Limulus Rhodopsin J. Biol. Chem., October 17, 2003; 278(42): 40493 - 40502. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Natochin, K. G. Gasimov, M. Moussaif, and N. O. Artemyev Rhodopsin Determinants for Transducin Activation: A GAIN-OF-FUNCTION APPROACH J. Biol. Chem., September 26, 2003; 278(39): 37574 - 37581. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Boucard, M. Roy, M.-E. Beaulieu, P. Lavigne, E. Escher, G. Guillemette, and R. Leduc Constitutive Activation of the Angiotensin II Type 1 Receptor Alters the Spatial Proximity of Transmembrane 7 to the Ligand-binding Pocket J. Biol. Chem., September 19, 2003; 278(38): 36628 - 36636. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Y. Yan, M. A. Kazmi, Z. Ganim, J.-M. Hou, D. Pan, B. S. W. Chang, T. P. Sakmar, and R. A. Mathies Retinal counterion switch in the photoactivation of the G protein-coupled receptor rhodopsin PNAS, August 5, 2003; 100(16): 9262 - 9267. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. W. Chang Ancestral Gene Reconstruction and Synthesis of Ancient Rhodopsins in the Laboratory Integr. Comp. Biol., August 1, 2003; 43(4): 500 - 507. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Fritze, S. Filipek, V. Kuksa, K. Palczewski, K. P. Hofmann, and O. P. Ernst Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation PNAS, March 4, 2003; 100(5): 2290 - 2295. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. del Valle, E. Ramon, X. Canavate, P. Dias, and P. Garriga Zinc-induced Decrease of the Thermal Stability and Regeneration of Rhodopsin J. Biol. Chem., February 7, 2003; 278(7): 4719 - 4724. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-i. Miura, J. Zhang, J. Boros, and S. S. Karnik TM2-TM7 Interaction in Coupling Movement of Transmembrane Helices to Activation of the Angiotensin II Type-1 Receptor J. Biol. Chem., January 31, 2003; 278(6): 3720 - 3725. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Meacock, F. J.L. Lecomte, S. G. Crawshaw, and S. High Different Transmembrane Domains Associate with Distinct Endoplasmic Reticulum Components during Membrane Integration of a Polytopic Protein Mol. Biol. Cell, December 1, 2002; 13(12): 4114 - 4129. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Vogel, G.-B. Fan, S. Ludeke, F. Siebert, and M. Sheves A Nonbleachable Rhodopsin Analogue with a Slow Photocycle J. Biol. Chem., October 18, 2002; 277(43): 40222 - 40228. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. W. Chang, K. Jonsson, M. A. Kazmi, M. J. Donoghue, and T. P. Sakmar Recreating a Functional Ancestral Archosaur Visual Pigment Mol. Biol. Evol., September 1, 2002; 19(9): 1483 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Kijas, A. V. Cideciyan, T. S. Aleman, M. J. Pianta, S. E. Pearce-Kelling, B. J. Miller, S. G. Jacobson, G. D. Aguirre, and G. M. Acland Naturally occurring rhodopsin mutation in the dog causes retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa PNAS, April 30, 2002; 99(9): 6328 - 6333. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Kijas, A. V. Cideciyan, T. S. Aleman, M. J. Pianta, S. E. Pearce-Kelling, B. J. Miller, S. G. Jacobson, G. D. Aguirre, and G. M. Acland Naturally occurring rhodopsin mutation in the dog causes retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa PNAS, April 30, 2002; 99(9): 6328 - 6333. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |